10-K/A 1 p18314_10ka.txt AMENDMENT TO ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT NO. 1 (Mark one) X Annual Report Pursuant to Section 13 or 15(d) of the --------------- Securities Exchange Act of 1934 for the Fiscal Year Ended December 31, 2002 OR Transition Report Pursuant to Section 13 or 15(d) of the ---------------- Securities Exchange Act of 1934 Commission File Number 000-26372 CELLEGY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) California 82-0429727 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 349 Oyster Point Boulevard, Suite 200, South San Francisco, California 94080 (Address of Principal ExecutiveOffices) (zip code) Registrant's telephone number, including area code: (650) 616-2200 Securities registered pursuant to Section 12(b) of the Act: None NASDAQ National Market (Title of each class) (Name of each exchange on which registered) Securities registered pursuant to Section 12(g) of the Act: Common Stock, no par value (Title of class) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES X NO --------- ------- Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [x] Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 under the Securities Exchange Act of 1934). YES _____ NO __X___ The aggregate market value of the voting stock held by non-affiliates of the Registrant as of June 28, 2002, the last business day of the Registrant's most recently completed second fiscal quarter, was $27,767,037 based on the closing price for the common stock on The Nasdaq Stock Market on such date. This calculation does not include a determination that persons are affiliates or non-affiliates for any other purpose. As of March 11, 2003, there were 19,889,946 of shares of common stock outstanding. Documents Incorporated By Reference The information called for by Part III, other than Item 14, and certain information called for by Part II, Item 5, is incorporated by reference to the definitive Proxy Statement for the Annual Meeting of Shareholders of the Company which will be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2002. CELLEGY PHARMACEUTICALS, INC. 10-K/A ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2002 TABLE OF CONTENTS Page ---- Part II Item 6. SELECTED FINANCIAL DATA .......................................... 3 Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ........................................ 4 Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA ...................... 13 Part IV Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.. 14 EXPLANATORY NOTE Cellegy Pharmaceuticals, Inc. (the "Company") is filing this Amendment No. 1 to Form 10-K (the "Amended Form 10-K/A") to amend and restate the financial statements and certain items within Parts II and IV contained in the Company's Annual Report on Form 10-K (the "Original Form 10-K") relating to the Company's year ended December 31, 2002 as originally filed with the Securities and Exchange Commission on March 21, 2003. The Amended Form 10-K/A reflects the restatement of the Company's audited consolidated financial statements as of December 31, 2002, and related changes in the Management's Discussion and Analysis of Financial Condition and Results of Operations. In the course of preparing its financial statements for the year ended December 31, 2003, the Company determined that it was necessary to adjust the accounting treatment for certain employee and director stock options that had been cancelled during the fourth quarter of 2002. The Company initially accounted for the cancellation of certain unvested options as a modification to the stock options and applied variable accounting treatment to the uncancelled portion of the stock options. Subsequently, the Company determined that was not the appropriate application under generally accepted accounting principles, and reversed the $695,000 of expense previously recorded in the fourth quarter of 2002 related to the intrinsic value of the vested options. Cellegy will also file amended quarterly reports on Form 10-Q/A for each of the first three quarters of 2003. A summary of the effect of this adjustment on the 2002 financial statements is as follows: in the statement of operations, research and development expense, selling, general and administrative expense and the net loss were reduced by $269,000, $426,000 and $695,000 respectively, on the consolidated balance sheet, common stock and the accumulated deficit were both reduced by $695,000. This Amended Form 10-K/A does not attempt to modify or update any other disclosures set forth in the Original Form 10-K, except as required to reflect the effects of the restatement described above and in note 13 to the financial statements included in this Amended Form 10-K/A. Additionally, this Amended Form 10-K/A does not purport to provide a general update or discussion of any other developments at the Company after the date of the original filing. All information contained in this Amended Form 10-K/A and the Original Form 10-K is subject to updating and supplementing as provided in the periodic reports that the Company has filed and will file after the original filing date with the Securities and Exchange Commission. In addition, the filing of this Amended Form 10-K/A shall not be deemed an admission that the original filing, when made, included any untrue statement of material fact or omitted to state a material fact necessary to make a statement made therein not misleading. This Amended Form 10-K/A does not include the items from the Original Form 10-K that are not being amended. 2 PART II ITEM 6: SELECTED FINANCIAL DATA The following selected historical information has been derived from audited financial statements of Cellegy. The financial information as of December 31, 2002 and 2001 and for each of the three earlier years in the period ended December 31 are derived from audited financial statements. The financial statements, related notes thereto, and the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this Form 10-K/A should be read carefully. The selected data is not intended to replace the financial statements.
($000's) Years ended December 31, ---------------------------------------------------------------------- 2002 2001 2000 1999 1998 ---- ---- ---- ---- ---- (Restated)(3) Statement of Operations Data: Revenues ............................... $ 1,402 $ 877 $ 1,586 $ 1,045 $ 832 Costs and expenses (1) ................. 17,163 21,847 13,573 10,847 9,266 -------- -------- -------- -------- -------- Loss from operations ................... (15,761) (20,970) (11,987) (9,802) (8,434) Interest income and other net and interest expense ..................... 520 1,505 569 501 1,068 -------- -------- -------- -------- -------- Net loss ............................... $(15,241) $(19,465) $(11,418) $ (9,301) $ (7,366) ======== ======== ======== ======== ======== Basic and diluted net loss per common share .................................. $ (0.86) $ (1.26) $ (0.91) $ (0.85) $ (0.73) ======== ======== ======== ======== ======== Weighted average common shares outstanding .......................... 17,643 15,503 12,542 10,914 10,160
(1) For the year ended December 31, 2002, Cellegy recorded non-cash compensation expense totaling $321,702, with approximately $265,702 occurring in the fourth quarter. During the year ended December 31, 2001, we recorded non-cash charges of $3,507,134 for in-process research and development associated with the Vaxis acquisition and $750,000 in non-cash charges for research and development expenses associated with milestone payments to Neptune Pharmaceuticals.
December 31, -------------------------------------------------------------------- 2002 2001 2000 1999 1998 --------- --------- --------- --------- --------- (Restated)(3) Balance Sheet Data: Cash, cash equivalents and investments (2) $ 23,858 $ 17,190 $ 15,923 $ 16,737 $ 15,220 Total assets .............................. 28,379 22,367 21,259 20,913 19,484 Deficit accumulated during the development stage ....................... (85,617) (70,377) (50,912) (39,494) (30,192) Total shareholders' equity ................ $ 10,534 $ 19,845 $ 18,794 $ 15,839 $ 14,218
(2) Includes restricted cash of $227,500 in 2002 and $614,000 in 2001. (3) See Footnote 13 in the Notes to Consolidated Financial Statements 3 ITEM 7: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Annual Report includes forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions. Words such as "believes," "anticipates," "expects," "intends" and similar expressions are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. Our "Management's Discussion and Analysis of Financial Condition and Results of Operations" contains many such forward-looking statements. These forward-looking statements are not guarantees of future performance and concern matters that involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include those described in "Management's Discussion and Analysis of Financial Condition and Results of Operations - Factors That May Affect Future Operating Results" and elsewhere in this Annual Report. Except as required by law, we undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that may arise after the date of this Annual Report. Actual events or results may differ materially from those discussed in this Annual Report. Cellegy Pharmaceuticals, Inc., a specialty biopharmaceutical company incorporated in California in 1989, is engaged in the development of prescription drugs and skin care products. We are developing several prescription drugs, including two transdermal testosterone gel products, Tostrex, for the treatment of male hypogonadism, a condition that afflicts certain men, generally above the age of forty, and Tostrelle, for the treatment of sexual dysfunction in menopausal women. Cellegesic is our nitroglycerin-based product for the treatment of anal fissures and hemorrhoids. The Consolidated Financial Statements as of and for the year ended December 31, 2002 and the notes thereto included in this Amended Form 10K/A have been restated. For additional information regarding the restatement, please refer to Note 13 to the Consolidated Financial Statements included in Item 8. All applicable financial information presented in this Item 7 has been restated to take into account the effects of the restatement described in Note 13 to the Consolidated Financial Statements. General In November 2001, we acquired a private Canadian based company, Vaxis Therapeutics, valued at $4.1 million. The purchase was payable primarily in shares of Cellegy stock. The purchase price was allocated to net tangible assets of $250,000, intangible assets of $350,000 and $3,507,000 million of in-process research and development. The intangibles of $350,000 are being amortized over five years and the in-process research and development has been expensed in the fourth quarter of 2001. The acquired technology was in an early stage of development such that, as of the acquisition date, technological feasibility had not been reached and no alternative use existed. The assumptions used in determining the purchase price allocation were based on an appropriate discount rate applied to expected cash flows. The purchase agreement provides for future earn-out payments over a period of seven years that are based on commercial sales of any products developed by Cellegy based on technologies acquired from Vaxis. Any contingent consideration paid in the future will be accounted for as a cost of earning the related revenues. The results of operations of the acquired company have been included in our consolidated financial statements since the acquisition date. In September 2002, Cellegy and Ventiv Health, Inc. terminated the Cellegesic License Agreement based on the delay in commercialization of Cellegesic due to the withdrawal of the NDA and the subsequent decision to conduct another Phase III trial. Cellegy and Ventiv originally signed a six year agreement to commercialize Cellegesic, in the United States in August 2001. Ventiv was to have delivered integrated marketing and sales solutions providing pre-launch support, recruiting and training a sales force which would have been jointly managed by both companies. 4 In November 2002, we completed a private placement of 2.2 million shares of our common stock resulting in approximately $5.5 million of gross proceeds to Cellegy. The financing was with a single investor, John M. Gregory, founder and former CEO of King Pharmaceuticals and currently managing partner of SJ Strategic Investments LLC. In December 2002, Cellegy entered into an exclusive license agreement with PDI, Inc. to commercialize Tostrex in North American markets. Under the terms of the agreement, PDI's Pharmaceutical Products Group will be responsible for the marketing and sale of Tostrex and utilizing its existing sales and marketing infrastructure and skills contained within the PDI Pharmaceutical Products Group. Cellegy received a payment of $15.0 million upon signing of the agreement on December 31, 2002 and will receive a milestone payment of $10.0 million upon approval of the product by the FDA in the United States. PDI will also make royalty payments on net sales ranging from 20% to 30%. Cellegy will be responsible for supplying finished product to PDI through Cellegy's contract manufacturer. Critical Accounting Policies Use of Estimates. The preparation of consolidated financial statements, in conformity with accounting principles generally accepted in the United States, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. We have identified below some of our more significant accounting policies. For further discussion of our accounting policies, see Note 1 in the Notes to Consolidated Financial Statements. Revenue Recognition. Revenues related to cost reimbursement provisions under development contracts are recognized as the costs associated with the projects are incurred. Revenues related to milestones specified under development contracts are recognized as the milestones are achieved. Cellegy has received certain government grants that support our research effort in defined research projects. These grants generally provide for reimbursement of approved costs incurred as defined in the various grants. Revenues associated with these grants are recognized as costs under each grant are incurred. Revenues related to product sales are recognized upon shipment when title to the goods has been transferred to the customer. There is no right of return for our Rectogesic and skin care product sales. Up-front payments, such as the $15.0 million payment received from PDI for the Tostrex license, are recorded as deferred revenue at the time the cash is received. Amounts are recognized as revenue on a straight-line basis over the longer of the life of the contract or the service period. Royalties payable to Cellegy under the PDI License Agreement will be recognized as earned when the royalties are no longer refundable to PDI under certain minimum royalty terms defined in the agreement. Long-Lived and Intangible Assets and Goodwill. Goodwill of $814,000 and other intangible assets of $382,000 are included in our December 31, 2002 balance sheet. Management reviews goodwill for impairment either on an annual basis or quarterly if an event occurs that might reduce the fair value of the long-lived asset below its carrying value. All other long-lived and intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of the asset may not be recoverable. An impairment loss would be recognized based on the difference between the carrying value of the asset and its estimated fair value, which would be determined based on either discounted future cash flows or other appropriate fair value methods. The evaluation of goodwill and other intangibles for impairment requires management to use significant judgments and estimates including, but not limited to, projected future revenue, operating results, and cash flows. Although management currently believes that the estimates used in the evaluation of goodwill and other intangibles are reasonable, differences between actual and expected revenue, operating results, and cash flow could cause these assets to be deemed impaired. If an impairment were to occur, Cellegy would be required to charge to earnings the write-down in value of such assets, which could have a material adverse effect on our results of operations and financial position. Clinical Trial Expenses. Clinical trial expenses are payable to clinical sites and clinical research organizations. Expenses for both of these groups are accrued on a straight-line basis over the contracted period subject to adjustment for actual activity based on such factors as the number of subjects enrolled and number of subjects that have completed treatment for each trial. A monthly reconciliation of costs accrued to cost incurred is performed by Cellegy's clinical project managers and the finance department. However, if activity levels associated with trials at a 5 given point in time are underestimated, we would have to record additional research and development expenses in future periods that could be significant. Investment Policy. Cellegy is subject to certain credit risk from our investment in marketable securities. By policy, we restrict amounts invested by investment type and by issuer, except for securities issued by the United States government. Cellegy has an investment policy that is approved and periodically reviewed by our Audit Committee. The policy states that investments must be highly liquid with maturities of less than three years. Cellegy's policy limits investments to the following: direct obligations of the United States Government or fully guaranteed by a government agency or by any of the states. Investments must have a rating of A1/P1 or A by Standard and Poors (or an equivalent rating); money market instruments must be a member of the Federal Reserve System with a net worth of at least $100 million and a rating of A1/AA by Standard and Poors (or equivalent rating). Any exception to the above requires approval of the Chief Financial Officer and the Chief Executive Officer. Results of Operations Years Ended December 31, 2002, 2001 and 2000 Revenues. Cellegy had revenues of $1,402,000, $877,000, and $1,586,000 in 2002, 2001 and 2000, respectively. Revenues in 2002 consisted of $1,081,000, relating to product sales primarily to Gryphon Development ("Gryphon"), the product development arm of a major specialty retailer, $275,000 in Rectogesic ointment sales in Australia and $46,000 in Canadian government grants. Revenues in 2001 consisted of $660,000 in product sales to Gryphon and $217,000 in Rectogesic sales in Australia. Revenues in 2000 consisted of $1,389,000 in product sales to Gryphon, $125,000 in Rectogesic sales and $72,000 in SBIR grant funding. The increase of $525,000 in total revenues in 2002 compared with 2001 was primarily due to a $421,000 or 64% increase in Gryphon sales relating to additional unit sales, a $58,000 or 27% increase in Rectogesic sales and a $46,000 increase in Canadian grants. The decrease of $709,000 in total revenue in 2001 compared with 2000 was primarily due to a $729,000 or 52% decrease in Gryphon sales, a $72,000 grant funding completed in 2000, offset by a $92,000 or 74% increase in Rectogesic sales. Research and Development Expenses. Research and development expenses were $10,403,000 in 2002 compared with $14,098,000 in 2001 and $9,574,000 in 2000. Total research and development expenses represented 58%, 65%, and 71% of our total operating expenses in 2002, 2001 and 2000, respectively. Total research and development expenses in 2002 compared with 2001 decreased by $3,695,000 or by 26%. The decrease was due to completion of the Cellegesic Phase III clinical trial and the completion of smaller Tostrex trials in 2001 and non-cash charges of $750,000 relating to milestone payments made to Neptune Pharmaceuticals in 2001. The increase of $829,000 or 9% in 2002 compared with 2000 was primarily due to spending associated with the Tostrex Phase III NDA filing costs and non-cash compensation charges relating to stock options. Research and development expenses include salaries and benefits, laboratory supplies, external research programs, clinical studies and allocated overhead costs such as rent, supplies and utilities. In addition to clinical site payments, clinical costs include the manufacturing of clinical supplies and related costs associated with product testing stability studies. We expect our research and development expenses in 2003 to be approximately equal to 2002 levels. Major expenses are planned for our Phase II/III Tostrelle clinical study, the pending Cellegesic Phase III trial, and for support of ongoing research in Cellegy Canada. Unexpected increases in research and development expenses may occur if the FDA requires further trials to support our NDA for Tostrex. Selling, General and Administrative Expenses. Selling, general and administrative expenses were $6,390,000 in 2002 compared with $4,042,000 in 2001 and $3,631,000 in 2000. The increases in 2002 compared with both 2001 and 2000 consisted primarily of sales and marketing expenses totaling $2,094,000 primarily related to Cellegesic pre-launch activities in the first half of 2002. In addition, we incurred investment banking fees, slightly offset by decreases in general office expenses. Our selling, general and administrative expenses are expected to increase in the second half of 2003 in support of our business development programs and product commercialization efforts. Acquired-In-Process Research and Development. Acquired-in-process research and development expenses of $3,507,000 were incurred during 2001 as a result of the Vaxis acquisition. There were no acquired-in-process research and development expenses incurred during 2002 and 2000. The acquired technology was at an early state of 6 development such that, at the acquisition date, technological feasibility had not been reached and no alternative use existed. Interest Income and Other Net and Interest Expense. Cellegy recognized $548,000 in interest income and other net, for 2002, compared with $1,532,000 in 2001, and $770,000 for 2000. Reductions in interest income were tied primarily to lower average investment balances, interest rates and rental income during 2002. Interest expenses were approximately $27,000 in both 2002 and 2001 and $201,000 in 2000. Interest expenses for 2002 and 2001 were related to the Ventiv loan and a separate commercial bank loan, respectively. Interest expense decreased by $174,000 in 2001 compared with 2000 due to the full repayment of commercial bank loan in 2001. Other income includes net rental income from our sub-lessees of $119,000 in 2002, $897,000 in 2001, and $80,000 in 2000. One of Cellegy's earlier sub-lease agreements expired in December 2001 and was replaced by a new sub-lease agreement which became effective in August 2002. Net Loss. The net loss in 2002 was $15,241,000 or $0.86 per share based on 17,643,000 weighted average shares outstanding compared with the net loss in 2001 of $19,465,000 or $1.26 per share based on 15,503,000 weighted average shares outstanding. In 2000, our net loss was $11,418,000 or $0.91 per share based on 12,542,000 weighted average shares outstanding. Liquidity and Capital Resources We have experienced net losses from operations each year since our inception. Through December 31, 2002, we had incurred an accumulated deficit of $85.6 million and had consumed cash from operations of $53.1 million. Cash from equity financing transactions have included $6.4 million in net proceeds from our initial public offering in August 1995, $6.8 million in net proceeds from a preferred stock financing in April 1996, $3.8 million in net proceeds from a private placement of common stock in July 1997, $13.8 million in net proceeds from a follow-on public offering in November 1997, $10.0 million in net proceeds from a private placement in July 1999, $11.6 million in net proceeds from a private placement in October 2000, $15.2 million in net proceeds from a private placement in June 2001 and $5.2 million in net proceeds from a private placement in November 2002. Our cash and investments were $23.9 million at December 31, 2002 compared with $17.2 million at December 31, 2001, including $227,000 and $614,000 of restricted cash, respectively. The increase in cash and investments of $6.6 million in 2002 was principally due to the net proceeds from the $5.2 million financing completed in November and $15.0 million in upfront payments from the licensing agreement with PDI in December, partially offset by other net cash used in operating activities of approximately $13.4 million. During the fourth quarter of 2002, we had an operating burn rate of approximately $800,000 per month; we expect the burn rate for the first quarter of 2003 to be at approximately the same level as the prior quarter. However, our operations have used and will continue to use increased amounts of cash in future quarters. Future expenditures and capital requirements depend on numerous factors including, without limitation, the progress and focus of our research and development programs, the progress and results of pre-clinical and clinical testing, the time and costs involved in obtaining regulatory approvals, the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, our ability to establish new collaborative arrangement and the initiation of commercialization activities and the purchase of capital equipment and working capital increases associated with the scale up and manufacture of Tostrex. We have a ten-year operating lease commitment on our facility with our current landlord. Our operating lease commitments are $1,288,000 for 2003 and $7,036,000 thereafter in annual amounts of approximately $1.3 to $1.5 million. Information about this commitment as of December 31, 2002 is presented in the table below (in thousands):
Contractual Obligations Total 2003 2004 - 2005 2006 - 2007 Thereafter ------------------ ------------- -------------- ---------------- --------------- ---------------- Operating lease $ 8,324 $ 1,288 $ 2,691 $ 2,854 $ 1,491
In order to complete the research and development and other activities necessary to commercialize our products, additional financing will be required. As a result, we will seek private or public equity investments and future collaborative arrangements or other transactions with third parties to meet such needs. There is no assurance that financing will be available for us to fund our operations on acceptable terms, if at all. Insufficient funding may 7 require us to delay, reduce or eliminate some or all of our research and development activities, planned clinical trials, marketing, sales, product promotion and administrative programs. We believe that available cash resources and the interest thereon will be adequate to satisfy our capital needs through at least December 31, 2004. Recent Accounting Pronouncements In December 2002, the Financial Accounting Standards Board issued Statement No. 148 ("FAS 148"), "Accounting for Stock-Based Compensation - Transition and Disclosure." FAS 148 amends FAS 123 "Accounting for Stock-Based Compensation" to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, FAS 148 amends the disclosure requirements of FAS 123 to require more prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The additional disclosure requirements of FAS 148 are effective for fiscal years ending after December 15, 2002. We have elected to continue to follow the intrinsic value method of accounting as prescribed by Accounting Principles Board Opinion No. 25 (or APB 25), "Accounting for Stock Issued to Employees," to account for employee stock options. Factors That May Affect Future Operating Results This report contains forward-looking statements that involve risks and uncertainties. Our actual results may differ significantly from the results discussed in this Annual Report. Factors that might cause such a difference include, but are not limited to, those discussed below. We are subject to regulation by regulatory authorities including the FDA, which could delay or prevent marketing of our products. Unexpected regulatory outcomes could adversely affect our business and stock price. Cellegy's prescription product candidates, and our ongoing research and clinical activities such as those relating to our product candidates Cellegesic, Tostrex and Tostrelle, are subject to extensive regulation by governmental regulatory authorities in the United States and other countries. Before we obtain regulatory approval for the commercial sale of our potential drug products, we must demonstrate through pre-clinical studies and clinical trials that the product is safe and efficacious for use in the clinical indication for which approval is sought. The timing of NDA submissions, the outcome of reviews by the FDA and the initiation and completion of other clinical trials are subject to uncertainty, change and unforeseen delays. Under the Prescription Drug User Fee Act, the FDA establishes a target date to complete its review of an NDA. Although the FDA attempts to respond by the relevant PDUFA date to companies which file NDAs, there is no assurance or obligation on the FDA's part to do so. For example, because Cellegy has not received feedback from the FDA on certain parts of our Tostrex NDA submission, the FDA could extend the approvability decision for this NDA beyond the current PDUFA date of April 6, 2003. In addition, extensive current pre-clinical and clinical testing requirements and the current regulatory approval process of the FDA in the United States and of certain foreign regulatory authorities, or new government regulations, could prevent or delay regulatory approval of Cellegy's products. The process of developing and obtaining approval for a new pharmaceutical product within this regulatory framework requires a number of years and the expenditure of substantial resources. There can be no assurance that necessary approvals will be obtained on a timely basis, if at all. Delays in obtaining regulatory approvals could have a material adverse effect on us. If we fail to comply with applicable regulatory requirements, we could be subject to a wide variety of serious administrative or judicially imposed sanctions and penalties, any of which would materially and adversely affect our business, results of operations and stock price. Disagreements may occur in the future, and one or more of our ongoing or planned clinical trials could be delayed or be required to be repeated in order to satisfy regulatory requirements. The FDA could impose requirements on future trials that could delay or prevent the regulatory approval process for Tostrex, Cellegesic or Tostrelle. For example, in June 2002, Cellegy announced that it had submitted an NDA for Tostrex including data from a Phase III clinical study using Tostrex to treat male hypogonadism. There can be no assurance that the FDA will find the trial data, the statistical analysis methodology used by Cellegy, or other sections of the NDA sufficient to approve Tostrex for marketing in the United States. The FDA could require further trials, decide to have an Advisory Panel review the submission, with an uncertain outcome of such panel's recommendation, or take other actions having the effect of delaying or preventing commercial introduction of Tostrex. If the FDA delays its 8 response beyond the current PDUFA date for our Tostrex NDA, our business plans and the market price of our common stock would be adversely affected. Sales of Cellegy's products outside the United States are subject to different regulatory requirements governing clinical trials and marketing approval. These requirements vary widely from country to country and could delay introduction of Cellegy's products in those countries. Our clinical trial results are very difficult to predict in advance, and the clinical trial process is subject to delays. Failure of one or more clinical trials or delays in trial completion could adversely affect our business and our stock price. Results of pre-clinical studies and early clinical trials may not be good predictors of results that will be obtained in later-stage clinical trials. We cannot assure you that Cellegy's present or future clinical trials, including, for example, the current Phase II/III study for Tostrelle, will demonstrate the results required to continue advanced trial development and allow us to seek marketing approval for this or our other product candidates. Because of the independent and blind nature of certain human clinical testing, there will be extended periods during the testing process when we will have only limited, or no, access to information about the status or results of the tests. Other pharmaceutical companies have believed that their products performed satisfactorily in early tests, only to find their performance in later tests, including Phase III clinical trials, to be inadequate or unsatisfactory, or that FDA Advisory Committees have declined to recommend approval of the drugs, or that the FDA itself refused approval, with the result that such companies' stock prices have fallen precipitously. Delays in the clinical trial process can be extremely costly in terms of lost sales opportunities and increased clinical trial costs. The speed with which we complete our clinical trials and our regulatory submissions, including NDAs, will depend on several factors, including the following: o the rate of patient enrollment, which is affected by the size of the patient population, the proximity of patients to clinical sites, the difficulty of the entry criteria for the study and the nature of the protocol; o the timely completion of clinical site protocol approval and obtaining informed consent from subjects; o analysis of data obtained from preclinical and clinical activities which could delay, limit or prevent regulatory approval; o changes in policies or staff personnel at regulatory agencies during the lengthy drug application review; and o the availability of experienced staff to conduct and monitor clinical studies, internally or through contract research organizations. We have a history of losses, and we expect losses to continue for at least several years. Our accumulated deficit as of December 31, 2002 was approximately $85.6 million. We have never operated profitably and, given our planned level of operating expenses, we expect to continue to incur losses for at least the next two years. We plan to increase our operating expenses as we continue to devote significant resources to pre-clinical studies, clinical trials, administrative, marketing, sales and patent activities. Accordingly, without substantial revenues from new corporate collaborations, royalties on product sales or other revenue sources, we expect to incur substantial operating losses in the foreseeable future as our potential products move into commercialization, and we continue to invest in research and clinical trials. Our losses may increase in the future, and even if we achieve our revenue targets, we may not be able to sustain or increase profitability on a quarterly or annual basis. The amount of future net losses, and the time required to reach profitability, are both highly uncertain. To achieve sustained profitable operations, we must, among other things, successfully discover, develop, obtain regulatory approvals for and market pharmaceutical products. We cannot assure you that we will ever be able to achieve or sustain profitability. Our prospects for obtaining additional financing, if required, are uncertain and failure to obtain needed financing could affect our ability to develop or market products. 9 Throughout our history, we have consumed substantial amounts of cash. Our cash needs are expected to continue to increase over, at least, the next two years in order to fund the additional expenses required to expand our current research and development programs and to commercialize our products once regulatory approvals have been obtained. Cellegy has no current source of significant ongoing revenues or capital beyond existing cash and investments, certain product sales of Rectogesic in Australia, sales to Gryphon, the development subsidiary of a major specialty retailer, and possible payments under our license agreement with PDI relating to Tostrex. In order to complete the research and development and other activities necessary to commercialize our products, additional financing will be required. Cellegy will seek private or public equity investments and future collaborative arrangements with third parties to help fund future cash needs. Such funding may not be available on acceptable terms, if at all. Including proceeds from a private placement financing during 2002 and upfront payments received from the Tostrex license agreement in the fourth quarter of 2002, Cellegy believes that available cash resources and interest earned will be adequate to satisfy its capital needs through at least December 31, 2004. The type and scope of patent coverage we have may limit the commercial success of our products. Cellegy's success depends, in part, on our ability to obtain patent protection for our products and methods, both in the United States and in other countries. Several of Cellegy's products and product candidates, such as Cellegesic, Tostrex and Tostrelle, are based on existing molecules with a history of use in humans but which are being developed by us for new therapeutic uses or in novel delivery systems which enhance therapeutic utility. We cannot obtain composition patent claims on the compounds themselves, and will instead need to rely on patent claims, if any, directed to use of the compound to treat certain conditions or to specific formulations. This is the case, for example, with our United States patents relating to Cellegesic and Tostrex. Such method-of-use patents may provide less protection than a composition-of-matter patent, because of the possibility of "off-label" use of the composition. Cellegy may not be able to prevent a competitor from using a different formulation or compound for a different purpose. No assurance can be given that any additional patents will be issued to us, that the protection of any patents that may be issued in the future will be significant, or that current or future patents will be held valid if subsequently challenged. The patent position of companies engaged in businesses such as Cellegy's business generally is uncertain and involves complex legal and factual questions. There is a substantial backlog of patent applications at the United States Patent and Trademark Office ("USPTO"). Patents in the United States are issued to the party that is first to invent the claimed invention. There can be no assurance that any patent applications relating to Cellegy's products or methods will issue as patents, or, if issued, that the patents will not be challenged, invalidated or circumvented or that the rights granted thereunder will provide us a competitive advantage. For example, we earlier reported that two oppositions had been filed with the European Patent Office regarding our European patent protecting the manufacture and use of nitroglycerin ointment and related compounds for the treatment of anal disorders, including fissures and various hemorrhoidal conditions. An adverse outcome in either opposition proceeding could have a negative effect on Cellegy, impacting the success of our marketing efforts in Europe. In addition, many other organizations are engaged in research and product development efforts in drug delivery and topical formulations that may overlap with Cellegy's products. Such organizations may currently have, or may obtain in the future, legally blocking proprietary rights, including patent rights, in one or more products or methods under development or consideration by Cellegy. These rights may prevent us from commercializing technology, or may require Cellegy to obtain a license from the organizations to use the technology. Cellegy may not be able to obtain any such licenses that may be required on reasonable financial terms, if at all, and cannot be sure that the patents underlying any such licenses will be valid or enforceable. Moreover, the laws of certain foreign countries do not protect intellectual property rights relating to United States patents as extensively as those rights are protected in the United States. The issuance of a patent in one country does not assure the issuance of a patent with similar claims in another country, and claim interpretation and infringement laws vary among countries, so the extent of any patent protection is uncertain and may vary in different countries. As with other companies in the pharmaceutical industry, we are subject to the risk that persons located in other countries will engage in development, marketing or sales activities of products that would infringe our patent rights if such activities were in the United States. Our product sales strategy involving corporate partners is highly uncertain. 10 Cellegy is seeking to enter into agreements with corporate partners regarding commercialization of our lead product candidates. Other than the recently completed Tostrex license agreement with PDI, Cellegy does not currently have any other agreements with third parties to commercialize our product candidates. Cellegy may not be able to establish any such collaborative arrangements and we may not have the resources or the experience to successfully commercialize any such products on our own. Failure to enter into any such arrangements could prevent, delay or otherwise have a material adverse effect on our ability to develop and market Tostrex in markets outside of North America or other products that we desire to commercialize through third party arrangements. With the current and future planned corporate partner arrangements, we may rely on our partners to conduct clinical trials, obtain regulatory approvals and, if approved, manufacture, distribute, market or co-promote these products. However, reliance on third party partners can create risks to our product commercialization efforts. Once agreements are completed, particularly if they are completed at a relatively early stage of product development, Cellegy may have little or no control over the development or marketing of these potential products and little or no opportunity to review clinical data before or after public announcement of results. Further, any arrangements that may be established may not be successful. In its annual report on Form 10-K for the year ended December 31, 2002, PDI dislosed that on January 6, 2003, it was named as a defendant in a state court action by Auxilium Pharmaceuticals, Inc.; that Auxilium was seeking monetary damages and injunctive relief, based on several claims related to PDI's alleged breaches of its contract sales force agreement with Auxilium and claims that PDI misappropriated and is misappropriating Auxilium's trade secrets in connection with PDI's exclusive license agreement with us; that a hearing in Auxilium's preliminary injunction motion was conducted on February 11 through 13, 2003 and the court did not reach a decision; that final arguments in the hearing were scheduled for March 2003; that PDI intended to continue contesting the case vigorously; and that PDI believed the likelihood of any order enjoining PDI from marketing and selling under its agreement with us for any significant time was unlikely, as was the likelihood of any material damage award against PDI. An adverse outcome in that litigation might adversely affect PDI's ability to perform its obligations under our agreement with PDI and could have an adverse effect on our ability to timely and successfully introduce and commercialize our Tostrex product. We do not have any history of manufacturing products, and we have a limited number of critical suppliers. Cellegy has no direct experience in manufacturing commercial quantities of products and currently does not have any capacity to manufacture products on a large commercial scale. We currently rely on a limited number of contract manufacturers, primarily PanGeo Pharma, and suppliers to manufacture our formulations. Although we believe that there will be adequate third party manufacturers, there can be no assurance that we will be able to enter into acceptable agreements with them. In the future, we may not be able to obtain contract manufacturing on commercially acceptable terms for compounds or product formulations in the quantities we need. Manufacturing or quality control problems, lack of financial resources or qualified personnel could occur with our contract manufacturers causing product shipment delays, inadequate supply, or causing the contractor not to be able to maintain compliance with the FDA's current good manufacturing practice requirements necessary to continue manufacturing. Such problems could reduce product sales, result in substantial Cellegy liabilities under our Tostrex license agreement or otherwise adversely affect Cellegy's business and stock price. We face intense competition from larger companies, and in the future Cellegy may not have the resources required to develop innovative products. Cellegy's products are subject to competition from existing products. The pharmaceutical industry is subject to rapid and significant technological change. In the development and marketing of prescription drugs, Cellegy faces intense competition. Cellegy is much smaller in terms of size and resources than many of its competitors in the United States and abroad, which include, among others, major pharmaceutical, chemical, consumer product, specialty pharmaceutical and biotechnology companies, universities and other research institutions. Cellegy's competitors may succeed in developing technologies and products that are more effective than any that we are developing and could render Cellegy's technology and potential products obsolete and noncompetitive. Many of these competitors have substantially greater financial and technical resources, clinical production and marketing capabilities and regulatory experience. In addition, Cellegy's products are subject to competition from existing products. For example, Cellegy's Tostrex product, if commercialized in the United States, is expected to compete with two currently marketed testosterone gel products sold by Unimed/Solvay and Auxilium Pharmaceuticals, and a transdermal patch product sold by Watson Pharmaceuticals. Cellegy's Cellegesic 11 product, if commercialized, is expected to compete with over-the-counter products, such as Preparation H marketed by American Home Products, and various other prescription products. As a result, we cannot assure you that Cellegy's products under development will be able to compete successfully with existing products or innovative products under development by other organizations. We currently have no drug products we sell on our own and have limited sales and marketing experience. We may market certain of our products, if successfully developed and approved, through a direct sales force in the United States and through sales and marketing partnership or distribution arrangements outside the United States. Cellegy has very limited experience in sales, marketing or distribution. To market certain of our products directly, we may establish a direct sales force in the United States or obtain the assistance of our marketing partner. If we enter into marketing or licensing arrangements with established pharmaceutical companies, our revenues will be subject to the terms and conditions of such arrangements and will be dependent on the efforts of our partner. Cellegy may not be able to successfully establish a direct sales force, or our collaborators may not effectively market any of our products, and either circumstance could have a material adverse effect on our business and stock price. We have very limited staffing and will continue to be dependent upon key employees Our success is dependent upon the efforts of a small management team, including K. Michael Forrest, our chief executive officer. We have employment agreements with certain officers, but none of our officers is bound to remain employed for any specific term. We had a reduction in force of nine people in August 2002 and an additional five people in December 2002. If key individuals leave Cellegy, we could be adversely affected if suitable replacement personnel are not quickly recruited. Our future success depends upon our ability to continue to attract and retain qualified scientific, clinical, marketing and administrative personnel. There is competition for qualified personnel in all functional areas, and particularly intense competition in the San Francisco Bay Area where our principal facility is located, which make it difficult to attract and retain the qualified personnel necessary for the development and growth of our business. We are subject to the risk of product liability lawsuits. The testing, marketing and sale of human health care products entails an inherent risk of allegations of product liability. We are subject to the risk that substantial product liability claims could be asserted against us in the future. Cellegy has obtained $5 million in insurance coverage relating to our clinical trials. There can be no assurance that Cellegy will be able to obtain or maintain insurance on acceptable terms, particularly in overseas locations, for clinical and commercial activities or that any insurance obtained will provide adequate protection against potential liabilities. Our stock price could be volatile. Our stock price has from time to time experienced significant price and volume fluctuations, particularly during 2002 and the first quarter of 2003. Sometimes our stock price has varied depending on fluctuations in the Nasdaq Stock Market generally, and sometimes fluctuations have resulted from matters more specific to Cellegy, such as an announcement of clinical trial or regulatory results or other corporate developments. Announcements that could significantly impact our stock price include: o publicity or announcements regarding regulatory developments relating to our products under review, particularly relating to Tostrex or Cellegesic; o clinical trial results, such as results of the Tostrelle trial; o period-to-period fluctuations in our financial results, including our cash and investment balance, operating expenses, cash burn rate or revenues; or o negative announcements or financial constraints by our key suppliers, service providers or our corporate partners, particularly PDI. 12 ITEM 8: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA The financial statements required by Item 8 are set forth below on pages F-1 through F-26 of this report. 13 PART IV ITEM 15: EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K Exhibits (a) The following exhibits are attached hereto or incorporated herein by reference: Exhibit Number Exhibit Title ------ ------------- 2.1 Asset Purchase Agreement dated December 31, 1997 between the Company and Neptune Pharmaceutical Corporation. (Confidential treatment has been granted with respect to portions of this agreement. Incorporated by reference to Exhibit 4.4 of the Company's Registration Statement on Form S-3 file no. 333-46087 on February 11, 1998,as amended. 3.1 Amended and Restated Articles of Incorporation of the Company. (Incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form SB-2 (Registration No. 33-93288 LA) declared effective on August 11, 1995 (the "SB-2").) 3.2 Certificate of Amendment of Amended and Restated Articles of Incorporation filed with the California Secretary of State on August 6, 2002. 3.3 Bylaws of the Company. (Incorporated by reference to Exhibit 3.3 to the SB-2.) 4.1 Specimen Common Stock Certificate. (Incorporated by reference to Exhibit 4.1 to the SB-2.) *10.1 1992 Stock Option Plan. (Incorporated by reference to Exhibit 10.12 to the SB-2.) *10.2 1995 Equity Incentive Plan (Incorporated by reference to Exhibit 4.03 to the Company's Registration Statement on Form S-8 (Registration No. 333-91588 on June 28, 2002.) *10.3 1995 Directors' Stock Option Plan (Incorporated by reference to Exhibit 10.8 to the Company's Form 10-Q for fiscal quarter ended June 30, 2002.) 10.4 Loan and Security Agreement between Silicon Valley Bank and the Company dated June 10, 1998 (Incorporated by reference to Exhibit 10.01 to the Company's Form 10-QSB for the fiscal quarter ended June 30, 1998.) 10.5 Lease Agreement between the Company and TCNorthern California Inc. dated April 8, 1998 (Incorporated by reference to Exhibit 10.01 to the Company's Form 10-QSB for fiscal quarter ended March 31, 1998.) *10.6 Employment Agreement dated November 20, 1996, between the Company and K. Michael Forrest. (Incorporated by reference to Exhibit 10.19 to the Company's Form 10-KSB for fiscal year ended December 31, 1996 (the "1996 Form 10-KSB".) 10.7 Services Agreement dated as of August 10, 2001 by and among the Company, Ventiv Health Inc. and VIS Financial LLC. (Incorporated by reference to Exhibit 10.12 to the Company's Form 10-K for fiscal year ended December 31, 2001. Confidential treatment has been requested with respect to portions of this agreement.) 10.8 Funding Arrangement dated August 10, 2001 by and among the Company, Ventiv Health Inc. and VIS Financial LLC. ((Incorporated by reference to Exhibit 10.13 to the Company's Form 10-K for fiscal year ended December 31, 2001. Confidential treatment has been requested with respect to portions of this agreement.) 10.9 Share Purchase Agreement dated as of November 27, 2001, by and among the Company, Vaxis Therapeutics Corporation and certain stockholders of Vaxis. (Incorporated by reference to Exhibit 10.14 to the Company's Form 10-K for fiscal year ended December 31, 2001.) 10.10 Exclusive License Agreement dated as of December 31, 2002, by and between the Company and PDI, Inc. (Confidential treatment has been requested with respect to portions of this agreement.)** 14 21.1 Subsidiaries of the Registrant. ** 23.1 Consent of Ernst & Young LLP, Independent Auditors. 24.1 Power of Attorney (See signature page.) * Represents a management contract or compensatory plan or arrangement. ** Previously filed with the original Annual Report on Form 10-K for the year ended December 31, 2002. (b) Reports on Form 8-K A report on Form 8-K was filed by Cellegy on January 2, 2003 announcing our exclusive agreement with PDI, Inc. to commercialize Tostrex in North American markets. On January 13, 2003, we filed a Form 8-K announcing that Mr. Julian Baker and his brother, Dr. Felix Baker resigned from the Company's Board of Directors. On February 27, 2003, we filed a Report on Form 8-K to report our fourth quarter and year-end financial results. (c) Financial Statement Schedules All schedules are omitted because they are not applicable or the information required to be set forth therein is included in the financial statements or notes thereto. 15 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this amendment to report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on the 24 of March, 2004. CELLEGY PHARMACEUTICALS, INC. By: /s/ K. Michael Forrest --------------------------------------- K. Michael Forrest President and Chief Executive Officer Power of Attorney Each person whose signature appears below constitutes and appoints each of K. Michael Forrest and A. Richard Juelis, true and lawful attorneys-in-fact, each with the power of substitution, for him in any and all capacities, to sign amendments to this Report on Form 10-K/A, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and conforming all that said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue thereof. Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated.
Name Title Date ---- ----- ---- Principal Executive Officer: /s/ K. Michael Forrest* President, Chief Executive Officer and March 24, 2004 ----------------------------------------- Director K. Michael Forrest Principal Financial Officer and Principal Accounting Officer: /s/ A. Richard Juelis* Vice President, Finance, Chief Financial March 24, 2004 ----------------------------------------- Officer and Secretary A. Richard Juelis Directors: /s/ * Director March 24, 2004 ----------------------------------------- John Q. Adams, Sr. /s/ * Director March 24, 2004 ----------------------------------------- Tobi B. Klar, M.D. /s/ * Director March 24, 2004 ----------------------------------------- Robert B. Rothermel. /s/ * Director March 24, 2004 ----------------------------------------- Thomas M. Steinberg /s/ * Chairman of the Board March 24, 2004 ----------------------------------------- Richard C. Williams
*By K. Michael Forrest, Attorney-in-Fact. 16 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, K. Michael Forrest, certify that: 1. I have reviewed this Amendment No. 1 to annual report on Form 10-K/A of Cellegy Pharmaceuticals,Inc.; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; 3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and (15d-15(e)) for the registrant and we have: a) designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared; b) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and c) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors: a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial data; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: March 24, 2004 By: /s/ K. Michael Forrest ---------------------- President and Chief Executive Officer 17 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, A. Richard Juelis, certify that: 1. I have reviewed this Amendment No. 1 to annual report on Form 10-K/A of Cellegy Pharmaceuticals,Inc.; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report; 3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and (15d-15(e)) for the registrant and we have: a) designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared; b) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially effected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors : a) all significant deficiencies and material weakness in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial data; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: March 24, 2004 By: /s/ A. Richard Juelis --------------------- Vice President, Finance and Chief Financial Officer 18 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with this Amendment No. 1 to annual report on Form 10-K/A of Cellegy Pharmaceuticals, Inc. (the "Company") for the period ended December 31, 2002, as filed with the United States Securities and Exchange Commission on the date hereof (the "Report"), K. Michael Forrest, as President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: i. The Report fully complied with the requirements of sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and ii. The information contained in the Report fairly presents, in all material respects, the financial Condition and results of operations of the Company: By: /s/ K. Michael Forrest ---------------------- K. Michael Forrest President and Chief Executive Officer Date: March 24, 2004 19 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with this Amendment No. 1 to annual report on Form 10-K/A of Cellegy Pharmaceuticals, Inc. (the "Company") for the period ended December 31, 2002, as filed with the United States Securities and Exchange Commission on the date hereof (the "Report"), A. Richard Juelis, as Vice President, Finance and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: iii. The Report fully complied with the requirements of sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and iv. The information contained in the Report fairly presents, in all material respects, the financial Condition and results of operations of the Company By: /s/ A. Richard Juelis --------------------- A. Richard Juelis Vice President, Finance and Chief Financial Officer Date: March 24, 2004 20 Index to Financial Statements Page ---- Report of Ernst & Young LLP, Independent Auditors ........................ F-2 Consolidated Balance Sheets .............................................. F-3 Consolidated Statements of Operations .................................... F-4 Consolidated Statements of Shareholders' Equity .......................... F-5 Consolidated Statements of Cash Flows .................................... F-9 Notes to Consolidated Financial Statements ............................... F-11 F-1 Report of Ernst & Young LLP, Independent Auditors The Board of Directors and Shareholders Cellegy Pharmaceuticals, Inc. We have audited the accompanying consolidated balance sheets of Cellegy Pharmaceuticals, Inc. (a development stage company) as of December 31, 2002 and 2001, and the related consolidated statements of operations, shareholders' equity and cash flows for each of the three years in the period ended December 31, 2002, and for the period from June 26, 1989 (inception) through December 31, 2002. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Cellegy Pharmaceuticals, Inc. (a development stage company) at December 31, 2002 and 2001 and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2002, and for the period from June 26, 1989 (inception) through December 31, 2002, in conformity with accounting principles generally accepted in the United States. The accompanying consolidated financial statements as of and for the year ended December 31, 2002 have been restated as discussed in Note 13. /s/ Ernst & Young LLP Palo Alto, California February 13, 2003 (except for Note 13, as to which the date is March 24, 2004) F-2 Cellegy Pharmaceuticals, Inc. (a development stage company) Consolidated Balance Sheets
December 31, -------------------------------- 2002 2001 ------------ ------------ Assets (Restated, see note 13) Current assets Cash and cash equivalents ............................................................. $ 21,628,517 $ 5,795,378 Short-term investments ................................................................ 2,002,123 4,053,280 Prepaid expenses and other current assets ............................................. 608,313 837,344 Total current assets ....................................................................... 24,238,953 10,686,002 Property and equipment, net ................................................................ 2,616,193 2,467,907 Long-term investments ...................................................................... -- 6,727,240 Restricted cash ............................................................................ 227,500 613,999 Intangible assets, net ..................................................................... 1,196,622 1,522,266 Other assets ............................................................................... 100,000 350,000 ------------ ------------ Total assets ............................................................................... $ 28,379,268 $ 22,367,414 ============ ============ Liabilities and Shareholders' Equity Current liabilities Accounts payable and accrued liabilities .............................................. $ 2,005,279 $ 1,893,253 Accrued compensation and related expenses ............................................. 122,925 144,614 Current portion of deferred revenue ................................................... 833,340 -- ------------ ------------ Total current liabilities .................................................................. 2,961,544 2,037,867 Long term liabilities ...................................................................... 716,619 484,826 Deferred revenue ........................................................................... 14,166,660 -- Commitments: (Note 4) Shareholders' equity Preferred stock, no par value; 5,000,000 shares authorized: Series A convertible preferred stock 1,100 shares designated; no shares issued or outstanding at December 31, 2002 and 2001 ...................................... -- -- Common stock, no par value; 35,000,000 shares authorized: 19,652,356 shares issued and outstanding at December 31, 2002 and 17,295,274 shares issued and outstanding at December 31, 2001 ....................................... 96,139,764 90,137,811 Accumulated other comprehensive income ................................................ 11,831 83,458 Deficit accumulated during the development stage ...................................... (85,617,150) (70,376,548) ------------ ------------ Total shareholders' equity ................................................................. 10,534,445 19,844,721 ------------ ------------ Total liabilities and shareholders' equity ................................................. $ 28,379,268 $ 22,367,414 ============ ============
See accompanying notes. F-3 Cellegy Pharmaceuticals, Inc. (a development stage company) Consolidated Statements of Operations
Period from June 26, 1989 Years ended December 31, through ------------------------------------------------ December 31, 2002 2001 2000 2002 ------------ ------------ ------------ ------------ Revenues: (Restated, see (Restated, see note 13) note 13) Licensing and contract revenue from affiliate ......... $ -- $ -- $ -- $ 1,145,373 Licensing, milestone, and development funding ......... -- -- -- 1,551,408 Government grants ..................................... 45,798 566 71,793 548,133 Product sales ......................................... 1,355,828 876,925 1,513,830 5,102,412 ------------ ------------ ------------ ------------ Total revenues ............................................. 1,401,626 877,491 1,585,623 8,347,326 Costs and expenses: Cost of products sold ................................. 369,992 200,338 368,113 1,320,874 Research and development .............................. 10,403,214 14,097,746 9,574,293 61,617,384 Selling, general and administrative ................... 6,389,847 4,041,642 3,630,616 26,950,596 Acquired in-process research and development .......... -- 3,507,134 -- 7,350,102 ------------ ------------ ------------ ------------ Total costs and expenses ................................... 17,163,053 21,846,860 13,573,022 97,238,956 ------------ ------------ ------------ ------------ Operating loss ............................................. (15,761,427) (20,969,369) (11,987,399) (88,891,630) Other income (expense): Interest expense ...................................... (27,136) (27,283) (200,689) (1,503,729) Interest income and other, net ........................ 547,961 1,531,929 769,875 6,226,714 ------------ ------------ ------------ ------------ Net loss ................................................... (15,240,602) (19,464,723) (11,418,213) (84,168,645) Non-cash preferred dividends ............................... -- -- -- 1,448,505 ------------ ------------ ------------ ------------ Net loss applicable to common shareholders ................. $(15,240,602) $(19,464,723) $(11,418,213) $(85,617,150) ============ ============ ============ ============ Basic and diluted net loss per common share ........ $ (0.86) $ (1.26) $ (0.91) ============ ============ ============ Weighted average common shares used in computing basic and diluted net loss per common share ................ 17,642,640 15,502,918 12,542,232 ============ ============ ============
See accompanying notes. F-4 Cellegy Pharmaceuticals, Inc. (a development stage company) Consolidated Statements of Shareholders' Equity
Series A Convertible Series B Convertible Series C Convertible Preferred Stock Preferred Stock Preferred Stock -------------------------- -------------------------- -------------------------- Shares Amount Shares Amount Shares Amount ----------- ----------- ----------- ----------- ----------- ----------- Issuance of convertible preferred stock, net of issuance cost through December 31, 1999 ..................... 27,649 $ 6,801,730 -- $ -- 477,081 $ 4,978,505 Issuance of Series A convertible preferred stock and warrants to purchase 14,191 shares of Series A convertible preferred stock in exchange for convertible promissory notes and accrued interest through December 31, 1999 ..................... 625,845 1,199,536 -- -- -- -- Issuance of convertible preferred stock for services rendered, and license agreement through December 31, 1999 ..................... 50,110 173,198 -- -- -- -- Issuance of Series B convertible preferred stock in exchange for convertible promissory notes ...................... -- -- 12,750 114,000 -- -- Non-cash preferred dividends ............. -- 1,448,505 -- -- -- -- Conversion of preferred stock, including dividends, to common stock through December 31, 1999 ............. (703,604) (9,622,969) (12,750) (114,000) (477,081) (4,978,505) Issuance of warrants in connection with notes payable in financing .................. -- -- -- -- -- -- Issuance of common stock in connection with private placement of common stock in July 1997, net of issuance cost ......................... -- -- -- -- -- -- Issuance of common stock in connection with the public offering of common stock in November 1997, net of issuance cost ......................... -- -- -- -- -- -- Issuance of common stock in connection with the acquisition of Neptune Pharmaceutical ........................ -- -- -- -- -- --
Accumulated Deficit Other Accumulated Common Stock Comprehensiv During the Total ----------------------------- Income Development Shareholders' Shares Amount (Loss) Stage Equity ------ ------ ------ ----- ------ Issuance of convertible preferred stock, net of issuance cost through December 31, 1999 ........................... -- $ -- $ -- $ -- $11,780,235 Issuance of Series A convertible preferred stock and warrants to purchase 14,191 shares of Series A convertible preferred stock in exchange for convertible promissory notes and accrued interest through December 31, 1999 ........................... -- -- -- -- 1,199,536 Issuance of convertible preferred stock for services rendered, and license agreement through December 31, 1999 ........................... -- -- -- -- 173,198 Issuance of Series B convertible preferred stock in exchange for convertible promissory notes ............................ -- -- -- -- 114,000 Non-cash preferred dividends ................... -- -- -- (1,448,505) -- Conversion of preferred stock, including dividends, to common stock through December 31, 1999 ................... 3,014,644 14,715,474 -- -- -- Issuance of warrants in connection with notes payable in financing ........................ -- 487,333 -- -- 487,333 Issuance of common stock in connection with private placement of common stock in July 1997, net of issuance cost ............................... 1,547,827 3,814,741 -- -- 3,814,741 Issuance of common stock in connection with the public offering of common stock in November 1997, net of issuance cost ............................... 2,012,500 13,764,069 -- -- 13,764,069 Issuance of common stock in connection with the acquisition of Neptune Pharmaceutical .............................. 462,809 3,842,968 -- -- 3,842,968
See accompanying notes F-5 Cellegy Pharmaceuticals, Inc. (a development stage company) Consolidated Statements of Shareholders' Equity (Continued)
Series A Series B Series C Convertible Convertible Convertible Preferred Stock Preferred Stock Preferred Stock Common Stock ---------------- ---------------- ---------------- ------------------------- Shares Amount Shares Amount Shares Amount Shares Amount ------ ------ ------ ------ ------ ------ ------ ------ Issuance of common stock in connection with IPO in August 1995 ................ -- -- -- -- -- -- 1,322,500 6,383,785 Issuance of common stock for cash through December 31, 1999 ....................... -- -- -- -- -- -- 953,400 126,499 Issuance of common stock for services rendered through December 31, 1999 .......... -- -- -- -- -- -- 269,116 24,261 Issuance of common stock in connection with the private placement of common stock in July 1999, net of issuance cost ....................... -- -- -- -- -- -- 1,616,000 10,037,662 Repurchase of common shares in 1992 .................... -- -- -- -- -- -- (3,586) (324) Issuance of common stock in exchange for notes payable . -- -- -- -- -- -- 42,960 268,500 Exercise of warrants to purchase common stock ...... -- -- -- -- -- -- 496,253 602,679 Exercise of options to purchase common stock ...... -- -- -- -- -- -- 275,820 961,775 Compensation expense related to the extension of option exercise periods ........... -- -- -- -- -- -- -- 338,481 Unrealized loss in investments -- -- -- -- -- -- -- -- Net loss for the period June 26, 1989 (inception) to December 31, 1999 .......... -- -- -- -- -- -- -- -- Balances at December 31, 1999 . -- -- -- -- -- -- 12,010,242 55,367,903 Issuance of common stock in connection with the private placement of common stock in October 2000, net of issuance cost of $22,527 ................. -- -- -- -- -- -- 1,500,000 11,602,473 Exercise of warrants to purchase common stock ...... -- -- -- -- -- -- 62,833 315,800 Exercise of options to purchase common stock ...... -- -- -- -- -- -- 95,754 380,516
Accumulated Deficit Other Accumulated Comprehensive During the Total Income Development Shareholders' (Loss) Stage Equity ---------- ------- ----------- Issuance of common stock in connection with IPO in August 1995 ................ -- -- 6,383,785 Issuance of common stock for cash through December 31, 1999 ....................... -- -- 126,499 Issuance of common stock for services rendered through December 31, 1999 .......... -- -- 24,261 Issuance of common stock in connection with the private placement of common stock in July 1999, net of issuance cost ....................... -- -- 10,037,662 Repurchase of common shares in 1992 .................... -- -- (324) Issuance of common stock in exchange for notes payable . -- -- 268,500 Exercise of warrants to purchase common stock ...... -- -- 602,679 Exercise of options to purchase common stock ...... -- -- 961,775 Compensation expense related to the extension of option exercise periods ........... -- -- 338,481 Unrealized loss in investments (35,471) -- (35,471) Net loss for the period June 26, 1989 (inception) to December 31, 1999 .......... -- (38,045,107) (38,045,107) ----------- ----------- Balances at December 31, 1999 . (35,471) (39,493,612) (15,838,920) Issuance of common stock in connection with the private placement of common stock in October 2000, net of issuance cost of $22,527 ................. -- -- 11,602,473 Exercise of warrants to purchase common stock ...... -- -- 315,800 Exercise of options to purchase common stock ...... -- -- 380,516
See accompanying notes. F-6 Cellegy Pharmaceuticals, Inc. (a development stage company) Consolidated Statements of Shareholders' Equity (Continued)
Series A Series B Series C Convertible Convertible Convertible Preferred Stock Preferred Stock Preferred Stock Common Stock ---------------- ---------------- ---------------- ---------------------- Shares Amount Shares Amount Shares Amount Shares Amount ------ ------ ------ ------ ------ ------ ------ ------ Fair value of warrants issued in Quay acquisition ....... -- -- -- -- -- -- -- 489,477 Common stock issued in connection with Quay acquisition ............... -- -- -- -- -- -- 169,224 977,105 Compensation expense related to warrants and options granted to non-employees .. -- -- -- -- -- -- -- 601,748 Unrealized gain on investments -- -- -- -- -- -- -- -- Foreign currency translation . -- -- -- -- -- -- -- -- Net loss ..................... -- -- -- -- -- -- -- -- Total Comprehensive Loss ..... -- -- -- -- -- -- -- -- Balances at December 31, 2000 -- -- -- -- -- -- 13,838,053 69,735,022 Issuance of common stock in connection with the private placement of common stock in June 2001, net of issuance costs of 184,795 ................ -- -- -- -- -- -- 2,747,143 15,199,206 Exercise of warrants to purchase common stock ..... -- -- -- -- -- -- 12,000 48,000 Exercise of options to purchase common stock ..... -- -- -- -- -- -- 60,803 203,437 Common stock issued in connection with Vaxis acquisition ............... -- -- -- -- -- -- 533,612 3,852,631 Compensation expense related to warrants and options granted to non-employees .. -- -- -- -- -- -- -- 349,515
Accumulated Deficit Other Accumulated Comprehensive During the Total Income Development Shareholders' (Loss) Stage Equity ---------- ------- ----------- Fair value of warrants issued in Quay acquisition ....... -- -- 489,477 Common stock issued in connection with Quay acquisition ............... -- -- 977,105 Compensation expense related to warrants and options granted to non-employees .. -- -- 601,748 Unrealized gain on investments 8,201 -- 8,201 Foreign currency translation . (1,537) -- (1,537) Net loss ..................... -- (11,418,213) (11,418,213) ----------- ----------- Total Comprehensive Loss ..... -- -- (11,411,549) ----------- Balances at December 31, 2000 (28,807) (50,911,825) 18,794,390 Issuance of common stock in connection with the private placement of common stock in June 2001, net of issuance costs of 184,795 ................ -- -- 15,199,206 Exercise of warrants to purchase common stock ..... -- -- 48,000 Exercise of options to purchase common stock ..... -- -- 203,437 Common stock issued in connection with Vaxis acquisition ............... -- -- 3,852,631 Compensation expense related to warrants and options granted to non-employees .. -- -- 349,515
See accompanying notes. F-7 Cellegy Pharmaceuticals, Inc. (a development stage company) Consolidated Statements of Shareholders' Equity (Continued)
Series A Series B Series C Convertible Convertible Convertible Preferred Stock Preferred Stock Preferred Stock Common Stock ---------------- ---------------- ---------------- ---------------------- Shares Amount Shares Amount Shares Amount Shares Amount ------ ------ ------ ------ ------ ------ ------ ------ Issuance of common stock in connection with the achievement of Neptune milestones ........................ -- -- -- -- -- -- 104,113 750,000 Unrealized gain/(loss) on investments ....................... -- -- -- -- -- -- -- -- Foreign currency translation ......... -- -- -- -- -- -- -- -- Net loss ............................. -- -- -- -- -- -- -- -- Total Comprehensive Loss ............. -- -- -- -- -- -- -- -- Balances at December 31, 2001 ........ -- -- -- -- -- -- 17,295,724 90,137,811 Exercise of options to purchase common stock ............. -- -- -- -- -- -- 156,632 454,983 Issuance of common stock in connection with the private placement of common stock in November 2002, net of issuance costs of $275,000 ................. -- -- -- -- -- -- 2,200,000 5,225,000 Compensation expense for options related to non-employees ..................... -- -- -- -- -- -- -- 72,224 Compensation expense related to stock option modifications (Restated) .......... -- -- -- -- -- -- -- 249,746 Unrealized gain (loss) on investments ....................... -- -- -- -- -- -- -- -- Foreign currency translation ......... -- -- -- -- -- -- -- Net loss (Restated) .................. -- -- -- -- -- -- -- -- Total Comprehensive Loss (Restated) ........................... -- -- -- -- -- -- -- -- Balances at December 31, 2002 (Restated) ........................ -- $ -- -- $ -- -- $ -- 19,652,356 $96,139,764 == ====== == ====== == ====== =========== ===========
Accumulated Deficit Other Accumulated Comprehensive During the Total Income Development Shareholders' (Loss) Stage Equity ------------ ------------ ------------ Issuance of common stock in connection with the achievement of Neptune milestones ............... -- -- 750,000 Unrealized gain/(loss) on investments .............. 130,655 -- 130,655 Foreign currency translation (18,390) -- (18,390) Net loss .................... -- (19,464,723) (19,464,723) ------------ ------------ Total Comprehensive Loss .... -- -- (19,352,458) ------------ Balances at December 31, 2001 83,458 (70,376,548) 19,844,721 Exercise of options to purchase common stock .... -- -- 454,983 Issuance of common stock in connection with the private placement of common stock in November 2002, net of issuance costs of $275,000 ........ -- -- 5,225,000 Compensation expense for options related to non-employees ............ -- -- 72,224 Compensation expense related to stock option modifications (Restated) . -- -- 249,746 Unrealized gain (loss) on investments .............. (82,916) -- (82,916) Foreign currency translation 11,289 -- 11,289 Net loss (Restated) ......... -- (15,240,602) (15,240,602) ------------ ------------ Total Comprehensive Loss (Restated) .................. -- -- (15,312,229) ------------ Balances at December 31, 2002 (Restated) ............... $ 11,831 $(85,617,150) $ 10,534,445 ============ ============ ============
See accompanying notes. F-8 Cellegy Pharmaceuticals, Inc. (a development stage company) Consolidated Statements of Cash Flows
Period from June 26, 1989 (inception) Years ended December 31, through -------------------------------------------------- December 31, 2002 2001 2000 2002 ------------ ------------ ------------ ------------ (Restated, see (Restated, see Operating activitiess note 13) note 13) ------------ ------------ ------------ ------------ Net loss ............................................... $(15,240,602) $(19,464,723) $(11,418,213) $(84,168,645) Adjustment to reconcile net loss to net cash used in operating activities: Acquired in-process technology ...................... -- 3,507,134 -- 7,350,102 Depreciation and amortization ....................... 484,028 530,643 502,470 2,229,116 Intangible assets amortization ...................... 325,644 359,673 298,351 983,668 Loss on sale of fixed assets ........................ (86,476) -- -- (86,476) Non-cash compensation expense related to warrants and options granted ............................... 321,970 349,516 601,748 1,273,234 Compensation expense related to option grants ....... -- -- -- 338,481 Amortization of discount on notes payable and deferred financing costs .......................... -- -- -- 24,261 Issuance of common shares for services .............. -- -- -- 990,918 Issuance of common stock for services rendered, interest, and Neptune milestones .................. -- 750,000 -- 567,503 Changes in operating assets and liabilities: Prepaid expenses and other current assets ........ 229,032 18,732 70,250 (708,312) Other assets ..................................... 250,000 -- -- 250,000 Accounts payable and accrued liabilities ......... 112,026 450,023 729,227 2,005,279 Other long term liabilities ...................... 231,793 484,826 -- 716,619 Deferred revenue ................................. 15,000,000 -- -- 15,000,000 Accrued compensation and related expenses ........ (21,689) 5,541 32,850 122,925 ------------ ------------ ------------ ------------ Net cash provided by (used in) in operating activities . 1,605,726 (13,008,635) (9,183,317) (53,111,327) Investing activities Purchases of property and equipment .................... (733,175) (150,530) (201,106) (4,837,420) Purchases of investments ............................... -- (16,789,905) (10,575,000) (87,890,354) Sales of investments ................................... 6,706,769 7,500,000 9,549,557 38,175,646 Maturities of investments .............................. 2,000,000 4,980,239 10,500,000 47,617,759 Proceeds from sale of property and equipment ........... 187,337 -- -- 187,337 Acquisition of Vaxis and Quay .......................... -- (142,556) (369,000) (511,556) ------------ ------------ ------------ ------------ Net cash provided by (used in) investing activities .... 8,160,931 (4,602,752) 8,904,451 (7,258,588) Financing activities Proceeds from notes payable ............................ -- -- -- 8,047,424 Proceeds from restricted cash .......................... 386,499 -- -- 386,499 Repayment of notes payable ............................. -- (882,070) (3,152,828) (6,610,608) Net proceeds from issuance of common stock ............. 5,679,983 15,450,643 12,298,789 69,111,551 Other assets ........................................... -- -- (613,999) (613,999) Other long-term liabilities ............................ -- -- (218,993) -- Issuance of convertible preferred stock, net of issuance costs ......................................... -- -- -- 11,757,735 Deferred financing costs ............................... -- -- -- (80,170) ------------ ------------ ------------ ------------ Net cash provided by financing activities .............. 6,066,482 14,568,573 8,312,969 81,998,432 ------------ ------------ ------------ ------------ Net increase (decrease) in cash and cash equivalents ... 15,833,139 (3,042,814) 8,034,103 21,628,517 Cash and cash equivalents, beginning of period ......... 5,795,378 8,838,192 804,089 -- ------------ ------------ ------------ ------------ Cash and cash equivalents, end of period ............... $ 21,628,517 $ 5,795,378 $ 8,838,192 $ 21,628,517 ============ ============ ============ ============
F-9 Cellegy Pharmaceuticals, Inc. (a development stage company) Consolidated Statements of Cash Flows (Continued)
Period from June 26, 1989 through December 31, 2002 2001 2000 2002 ----------- ----------- ----------- ----------- Supplemental cash flow information Interest paid .......................................... $ 27,136 $ 27,281 $ 200,689 $ 639,987 =========== =========== =========== =========== Supplemental disclosure of non-cash transactions: Issuance of common stock in connection with acquired-in-process technology ...................... $ -- $ 3,507,134 $ -- $ 7,350,102 =========== =========== =========== =========== Conversion of preferred stock to common stock .......... $ -- $ -- $ -- $14,715,474 =========== =========== =========== =========== Issuance of common stock for notes payable ............. $ -- $ -- $ -- $ 277,250 =========== =========== =========== =========== Issuance of warrants in connection with notes payable financing ................................... $ -- $ -- $ -- $ 487,333 =========== =========== =========== =========== Issuance of convertible preferred stock for notes payable ....................................... $ -- $ -- $ -- $ 1,268,316 =========== =========== =========== =========== Issuance of common stock for milestone payments ........................................ $ -- $ 750,000 $ -- $ 750,000 =========== =========== =========== ===========
See accompanying notes. F-10 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements 1. Accounting Policies Description of Business and Principles of Consolidation The consolidated financial statements include the accounts of Cellegy Pharmaceuticals, Inc. and its subsidiaries (the "Company"). All significant inter-company balances and transactions have been eliminated in consolidation. The Company was incorporated in California in June 1989 and is a development stage company. Since its inception, the Company has engaged primarily in research and clinical development activities associated with its current and potential future products and its transdermal drug delivery and topical formulation expertise. The Company has conducted a number of clinical trials using its products, including the preparation of manufactured clinical materials. A number of sponsored, external research programs have been undertaken. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Revenue Recognition and Research and Development Expenses Revenues related to cost reimbursement provisions under development contracts are recognized as the costs associated with the projects are incurred. Revenues related to milestones specified under development contracts are recognized as the milestones are achieved. The Company receives certain United States government grants that support the Company's research effort in defined research projects. These grants generally provide for reimbursement of approved costs incurred as defined in the various grants. Revenues associated with these grants are recognized as costs under each grant are incurred. Revenues related to product sales are recognized upon shipment when title to goods has been transferred to the customer. There is no right of return for product sales. Up-front payments, such as the $15.0 million payment received from PDI for the Tostrex license, are recorded as deferred revenue at the time the cash is received. Amounts are recognized as revenue on a straight-line basis over the longer of the life of the contract or the service period. Royalties payable to Cellegy under the PDI License Agreement will be recognized as earned when the royalties are no longer refundable to PDI under certain minimum royalty terms defined in the agreement. Research and development costs are expensed as incurred. The type of costs included in research and development expenses include salaries and benefits, laboratory supplies, external research programs, clinical studies and allocated costs such as rent, supplies and utilities. Clinical trial expenses are payable to clinical sites and clinical research organizations. Expenses for both of these groups are accrued on a straight-line basis over the contracted period subject to adjustment for actual activity based on such factors as the number of subjects enrolled and number of subjects that have completed treatment for each trial. Cash, Cash Equivalents and Investments Cash equivalents consist of highly liquid financial instruments with original maturities of three months or less. The carrying value of cash and cash equivalents approximates fair value at December 31, 2002 and 2001. The Company considers all its investments as available-for-sale and reports these investments at estimated fair market value using available market information. Unrealized gains or losses on available-for-sale securities are included in shareholders' equity as other comprehensive income (loss) until their disposition. The cost of securities sold is based on the specific identification method. Realized gains or losses and declines in value judged to be other than temporary on available-for-sale securities are included in interest income and other, net. F-11 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) The Company is subject to credit risk from its portfolio of marketable securities. By policy, the Company restricts amounts invested in such securities by investment type and by issuer except for securities issued by the United States government. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Furniture and fixtures, and office and laboratory equipment are depreciated using the straight-line method over estimated useful lives ranging from three to five years. Amortization for leasehold improvements is taken over the shorter of the estimated useful life of the asset or the remaining lease term. Goodwill and Other Intangible Assets Goodwill that is related to the purchase of Quay Pharmaceuticals in June 2000, included in intangible assets, represents the excess purchase price over the fair value of net assets acquired which was being amortized over 10 years using the straight-line method. The carrying value of goodwill is based on management's current assessment of recoverability using objective and subjective factors. Effective January 1, 2002, the Company will no longer amortize the remaining balance of goodwill of $814,400. We performed an impairment test of goodwill upon transition to FAS 142 on January 1, 2002, and no impairment was found for either period. We will continue to evaluate our goodwill for impairment on an annual basis each year and whenever events and changes in circumstances suggest that the carrying amount may not be recoverable. An impairment loss, if needed, would be recognized based on the difference between the carrying value of the asset and its estimated fair value, which would be determined based on either discounted cash flows or other appropriate fair value methods. FAS 142 also requires that intangible assets with definite lives be amortized over their estimated useful lives and reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. We currently amortize our other intangible assets on a straight-line basis over their estimated useful lives ranging from three to five years. Amortization taken to date as of December 31, 2002 was approximately $983,000. Stock-Based Compensation The Company accounts for its stock option grants in accordance with Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" ("APB 25") and related Interpretations. The Company has elected to follow the disclosure-only alternative prescribed by Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation" ("FAS 123"). Under APB 25, because the exercise price of the Company's employee stock options equals the market price of the underlying stock on the date of grant, no compensation expense is recognized. Compensation for options granted to non-employees has been determined in accordance with FAS 123 and EITF 96-18 at the fair value of the equity instruments issued. Stock based compensation is recognized on a straight-line basis. Foreign Currency Translation The foreign subsidiaries functional currencies are their local currencies. The gains and losses resulting from translating the foreign subsidiaries' financial statements into US dollars have been reported in other comprehensive income (loss). Comprehensive Income (Loss) Comprehensive income (loss) consists of net loss and other comprehensive income (loss). Accumulated other comprehensive income (loss) presented in the consolidated balance sheets consists of the accumulated net unrealized gain (loss) on available-for-sale investments and foreign currency translation adjustments. Basic and Diluted Net Loss per Common Share Basic net loss per common share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share incorporates the incremental shares issued upon the assumed exercise of stock options and warrants, when dilutive. There is no difference between basic and diluted net loss per common share, as F-12 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) presented in the statement of operations, because all options and warrants are anti-dilutive. The total number of shares excluded was 1,864,551, 5,041,375 and 5,232,337 for the years ended December 31, 2002, 2001 and 2000, respectively. Recent Accounting Pronouncements In June 2002, the Financial Accounting Standards Board issued Financial Accounting Standard 146 ("FAS 146"), "Accounting for Costs Associated with Exit or Disposal Activities," which addresses accounting for restructuring, discontinued operation, plant closing, or other exit or disposal activity. FAS 146 requires companies to recognize costs associated with exit or disposal activities when they are incurred rather than at the date of a commitment to an exit or disposal plan. FAS 146 is to be applied prospectively to exit or disposal activities initiated after December 31, 2002. The adoption of FAS 146 is not expected to have a significant impact on our financial position and results of operations. In November 2002, the Financial Accounting Standards Board issued Interpretation No. 45 ("FIN 45"), "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others." FIN 45 elaborates on the existing disclosure requirements for most guarantees, including residual value guarantees issued in conjunction with operating lease agreements. It also clarifies that at the time a company issues a guarantee, the company must recognize an initial liability for the fair value of the obligation it assumes under that guarantee and must disclose that information in its interim and annual financial statements. The initial recognition and measurement provisions apply on a prospective basis to guarantees issued or modified after December 31, 2002. The disclosure requirements are effective for financial statements of interim or annual periods ending after December 15, 2002. Our adoption of FIN 45 did not have a material impact on our results of operations and financial position. In December 2002, the Financial Accounting Standards Board issued Statement No. 148 ("FAS 148"), "Accounting for Stock-Based Compensation - Transition and Disclosure." FAS 148 amends FAS 123 "Accounting for Stock-Based Compensation" to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, FAS 148 amends the disclosure requirements of FAS 123 to require more prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The additional disclosure requirements of FAS 148 are effective for fiscal years ending after December 15, 2002. We have elected to continue to follow the intrinsic value method of accounting as prescribed by Accounting Principles Board Opinion No. 25 (or APB 25), "Accounting for Stock Issued to Employees," to account for employee stock options. See below in the "Shareholders' Equity" note for the disclosures required by FAS 148. The Company has elected to follow APB Opinion No. 25 and related interpretations in accounting for its stock options since, as discussed below, the alternative fair market value accounting provided for under FAS 123 requires use of option valuation models that were not developed for use in valuing stock options. Under APB Opinion No. 25, if the exercise price of the Company's stock options is equal to the market price of the underlying stock on the date of grant, no compensation expense is recognized related to employee or director grants. Pro forma information regarding net loss and net loss per common share is required by FAS 123, which requires that the information be determined as if the Company has accounted for its common stock options granted under the fair market value method. The fair market value of options granted has been estimated at the date of the grant using a Black-Scholes option pricing model. The Company valued its options using the following weighted average assumptions for the years ended December 31, 2002, 2001 and 2000: 2002 2001 2000 ---- ---- ---- Risk-free interest rate .............. 2.5% 3.5% 6.0% Dividend yield ....................... 0% 0% 0% Volatility ........................... 1.06 0.60 0.91 Expected life of options in years .... 4.3 4.3 4.3 The Black-Scholes option pricing model was developed for use in estimating the fair market value of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. Because the Company's stock options have characteristics F-13 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair market value estimate. In management's opinion, the existing models do not necessarily provide a reliable single measure of the fair market value of its stock options. For purposes of pro forma disclosures, the estimated fair value of the options is amortized to expense over the options' vesting period. The Company's pro forma information for the years ended December 31 are as follows:
2002 2001 2000 (Restated, see note 13) ------------ ------------ ------------ Net loss as reported .......................................... $(15,240,602) $(19,464,723) $(11,418,213) ------------ Add: Stock-based employee compensation costs included in the determination of net loss, as reported ...................................... 249,746 -- -- Deduct: Stock-based employee compensation costs that would have been included in the determination of net loss if the fair value method had been applied to all awards ................................................. (2,227,933) (2,687,751) (1,686,989) ------------ ------------ ------------ Net loss, pro forma ........................................... $(17,218,789) $(22,152,474) $(13,105,202) Basic and diluted net loss per share, as reported ............. $ (0.86) $ (1.26) $ (0.91) Pro forma basic and diluted net loss per share ................ $ (0.98) $ (1.43) $ (1.04)
The weighted average grant date fair value of options granted during the years ended December 31, 2002, 2001, and 2000 was $3.80, $5.33 and $4.30, respectively. The weighted average remaining contractual life of those options is 9.0 years, 6.8 years and 7.2 years during the years ended December 31, 2002, 2001 and 2000, respectively. The effects of applying FAS 123 pro forma disclosures are not likely to be representative of the effects on reported net loss for future years. Reclassification Certain prior year balances have been reclassified for comparative purposes. 2. Investments At December 31, 2002 and 2001, investments consist of the following:
2002 2001 --------------------------------------------- --------------------------------------------- Gross Gross Unrealized Estimated Unrealized Estimated Cost Gains Fair Value Cost Gains Fair Value ----------- ----------- ----------- ----------- ----------- ----------- Corporate notes .............. $ 2,001,580 $ 543 $ 2,002,123 $ 6,678,378 $ 79,642 $ 6,758,020 U.S. government notes ........ -- -- -- 2,000,000 22,500 2,022,500 Commercial paper ............. -- -- -- 2,000,000 -- 2,000,000 ----------- ----------- ----------- ----------- ----------- ----------- $ 2,001,580 $ 543 $ 2,002,123 $10,678,378 $ 102,142 $10,780,520 =========== =========== =========== =========== =========== ===========
F-14 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) Property and equipment consist of the following: December 31, ------------------------------- 2002 2001 ----------- ----------- Furniture and fixtures ................. $ 184,305 $ 178,926 Office equipment ....................... 238,822 242,233 Laboratory equipment ................... 978,485 742,882 Leasehold improvements ................. 2,919,390 2,917,075 ----------- ----------- 4,321,002 4,081,116 Less accumulated depreciation and amortization ......................... (1,704,809) (1,613,209) ----------- ----------- $ 2,616,193 $ 2,467,907 =========== =========== 4. Lease Commitments The Company leases its facilities and certain equipment under non-cancelable operating leases. Rent expense is recorded on a straight-line basis over the term of the lease. During the third quarter of 2002, the Company subleased a portion of its facility. Rental income is recorded as received. Future minimum lease payments, net of future minimum sublease income at December 31, 2002, are as follows: Future Minimum Lease Sublease Lease Years ending December 31, Commitments Income Commitments ------------------------- ----------- ----------- ----------- 2003 .................... 1,287,948 (1,111,123) 176,825 2004 .................... 1,326,144 (1,174,738) 151,406 2005 .................... 1,365,468 (1,209,979) 155,489 2006 .................... 1,405,992 (1,246,278) 159,714 2007 .................... 1,447,716 (1,283,666) 164,050 Thereafter .............. 1,490,700 (1,322,175) 168,525 ----------- ----------- ----------- $ 8,323,968 $(7,347,959) $ 976,009 =========== =========== =========== Rent expense, net of sublease income, was $891,620, $1,653,337 and $1,817,427 for the years ended December 31, 2002, 2001, and 2000, respectively. The Company received $405,000 in sublease income during the year ended December 31, 2002. Restricted cash at December 31, 2002 and 2001 was approximately $227,500 and 614,000, respectively, and represents amounts that secure a letter of credit related to our leases. 5. 401(k) Plan The Company maintains a savings and retirement plan under Section 401(k) of the Internal Revenue Code. All employees are eligible to participate on their first day of employment with the Company. Under the plan, employees may contribute up to 15% of salaries per year subject to statutory limits. The Company provides a matching contribution equal to 25% of the employee's rate of contribution, up to a maximum contribution rate of 4% of the employee's annual salary. Expenses related to the plan for the years ended December 31, 2002, 2001 and 2000 were not significant. 6. Restructuring On July 23, 2002 and December 13, 2002 the Board of Directors formally adopted reduction in force programs affecting primarily research and marketing functions. The reductions resulted in a decrease of nine and five employees, respectively. During the third and fourth quarters, we recorded severance and other related charges of $210,000 and $143,000, respectively. In the fourth quarter, we recorded a stock based compensation charge of $250,000 related to the extension of the exercise period of certain options held by terminated employees. F-15 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) 7. Acquisitions, Licenses and Other Agreements Acquisitions In December 1997, the Company acquired patent and related intellectual property rights relating to Cellegesic (the "Agreement"), a topical product candidate for the treatment of anal fissures and hemorrhoids from Neptune Pharmaceuticals Corporation ("Neptune"). Under the terms of the Agreement, the Company issued 429,752 shares of common stock to Neptune on December 31, 1997. Upon the signing of a letter of intent on November 3, 1997, 33,057 shares of common stock were issued to Neptune. The Agreement calls for a series of additional payments, payable in shares of common stock, upon successful completion of various development milestones. Upon completion of milestones in 2001, the Company issued 104,113 shares of common stock valued at $750,000 which has been recorded to research and development expenses. The remaining milestones, if achieved, would become payable over the next several years. Depending on several factors, including the market price of the common stock, such payments, which are fixed based on the Agreement, could result in the issuance of a significant number of shares of common stock or cash. Future potential milestones, if all paid in Cellegy common stock could result in the issuance of up to an additional 1,285,000 shares of Cellegy common stock based on the closing price of Cellegy stock at time of issuance. The Agreement does not provide for the payment by the Company of any future product royalties in connection with sales of Cellegesic. In June 2000, Cellegy acquired all assets of Quay Pharmaceuticals Pty Ltd ("Quay"), an Australian pharmaceutical company producing Rectogesic, a drug similar to Cellegesic. The acquired assets consisted of Quay's inventory, purchased at Quay's cost at the time of acquisition, other tangible assets and purchased technology. The aggregate purchase price of $1,835,000 included the aggregate value of the 169,224 shares of Cellegy common stock issued to Quay with a value of $977,000, warrants to purchase 171,146 shares of common stock with a fair value of $489,000, and cash payments of $369,000. The purchase price was allocated to the net tangible assets of $97,000, purchased technology of $770,000, and goodwill of $968,000, based on their estimated fair values on the acquisition date. Purchased technology and goodwill were being amortized over three and ten years, respectively. Following the adoption of FAS 142, the goodwill will no longer be amortized as of January 1, 2002. This transaction has been accounted for by the purchase method of accounting and accordingly, the approximated purchase price, shown above, has been allocated to the net assets acquired and the liabilities assumed based on the estimated fair values at the date of acquisition, with the excess of the purchase price over assigned asset values recorded as goodwill. The results of operating the acquired company have been included in the Company's consolidated financial statements since the acquisition date. On November 27, 2001, Cellegy acquired Vaxis Therapeutics, a private Canadian company. Vaxis, renamed Cellegy Canada, is a small early stage research and development entity with access to scientists in the areas of sexual dysfunction, peripheral vascular disorders and nitric oxide pharmacology. The acquisition of this research is in line with the Company's goal of expanding its pipeline of products and protecting its patents. The purchase price of $4.1 million consisted of 533,612 shares of our common stock and $142,000 in cash. The purchase price was allocated as follows: $350,000 to intangible assets, $250,000 to tangible assets and $3,500,000 to acquired in-process research and development. The acquired technology was in an early stage of development that, as of the acquisition date, technological feasibility had not been reached and no alternative use existed. One of the assumptions used in determining the purchase price allocation was a discount rate of 37% on probability of expected cash flows. The intangible assets will be amortized over 5 years, the period of contractual obligation. The Vaxis purchase agreement contains earn-out provisions for seven years that are based on commercial sales of any products developed by the Company or other revenues generated from the acquired research. Any contingent consideration paid in the future will be accounted for as a cost of earning the related revenues. The results of operations of the acquired company have been included in the Company's consolidated financial statements since the acquisition date. Accumulated amortization of the Vaxis intangible assets at December 31, 2002 was $75,000. The expected amortization expense for Vaxis for the next four years will be approximately $68,800 per year. The expected amortization expense for Quay for the next year will be approximately $107,000. F-16 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) Other Agreements In October 1993, Cellegy entered into a license agreement with the University of California providing for an exclusive, worldwide, royalty bearing license, subject to customary government rights, for patent rights relating to barrier repair formulations jointly held by the University and Cellegy, in consideration of the issuance to the University of certain shares of preferred stock (which subsequently converted into shares of common stock) and the payment by Cellegy of a licensing fee. In March 1994, Cellegy entered into an exclusive, worldwide, royalty bearing license agreement with the University for patent rights, jointly held by the University of California and Cellegy, relating to certain drug delivery technologies, in consideration of the payment by Cellegy of a licensing fee, and an annual maintenance fee payable each year until Cellegy is commercially selling a licensed product. In April 2000, Cellegy terminated the Exclusive License Agreement relating to barrier repair formulations and assigned its rights in the invention to the University. We are now in the process of terminating our license patent right relating to drug delivery technologies and assigning the rights to the University. The termination of these licenses reflects, in part, a shift towards development of products from the Company's own research efforts in areas which we believe have the potential to be more commercially viable. In August 2001, Cellegy announced a comprehensive agreement with Ventiv Health, Inc. ("Ventiv"), a contract sales organization. Ventiv was to provide certain sales and marketing services relating to the anticipated launch of Cellegesic. In September 2002, Cellegy and Ventiv terminated the Cellegesic License Agreement based on the delay in commercialization of Cellegesic due to the withdrawal of the NDA and the subsequent decision to conduct another Phase III clinical trial. In December 31, 2002, Cellegy entered into a license agreement with PDI, Inc. granting PDI the exclusive right to store, promote, sell and distribute Tostrex, one of our products awaiting FDA approval, in North American markets. Cellegy received an upfront payment of $15.0 million on the effective date (December 31, 2002) and a payment of $10.0 million is due to us no later than thirty days after we certify to PDI that Tostrex has received all FDA approvals required to manufacture, sell and distribute the product in the United States. We have recorded financing costs of $947,000 to selling, general and administrative expenses for the year ended December 31, 2002 related to this agreement. If we receive the $10.0 million payment, we will incur additional financing costs of $600,000. Under the PDI agreement, Cellegy will also receive royalties each year until the expiration of the last patent right related to Tostrex of 20% - 30% of net sales and we will be reimbursed for 110% of burdened costs for any product supplied to PDI. The $15 million upfront payment has been included as deferred revenue as of December 31, 2002 and will be recognized as revenue over the 18 year term of the agreement. 8. Shareholders' Equity Common Stock Private Placements In October 2000, Cellegy completed a private placement of 1.5 million shares of common stock at a price of $7.75 per share to a group of institutional investors. Net proceeds were $11,602,473. In June 2001, we completed a private placement of approximately 2.7 million shares of common stock at a price of $5.60 per share. Participants included two current investors, as well as five new investors. Net proceeds were $15,199,206. In November 2002, we completed a private placement of approximately 2.2 million shares our common stock at a price of $2.50 per share to a single investor, John M. Gregory, founder and former CEO of King Pharmaceuticals and currently managing partner of SJ Strategic Investments LLC. Net proceeds were $5,225,000. Preferred Stock The Company's Articles of Incorporation provide that the Company may issue up to 5,000,000 shares of preferred stock in one or more series. The Board of Directors is authorized to establish from time to time the number of shares to be included in, and the designation of, any such series and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed upon any wholly unissued series of preferred stock and to increase or decrease the number of shares of any such series without any further vote or action by the shareholders. F-17 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) Stock Option Plans In 1995, Cellegy adopted the Equity Incentive Plan (the "Plan") to provide for the issuance of incentive stock options and non-statutory stock options. When the Plan was established, Cellegy reserved 700,000 shares for issuance. From 1996 to 2002, a total of 4,150,000 shares were reserved for issuance under the Plan. Options issued under the Plan have a term of 10 years and are generally subject to vesting over 3 years. Activity under the Plan is summarized as follows:
Shares Exercise Price Weighted Under Range Average Option Per Share Exercise Price ------ --------- -------------- Balance at January 1, 2000 ................................. 2,187,763 $0.50-$8.81 $4.82 Granted .................................................... 191,350 $3.31-$9.00 $6.21 Canceled ................................................... (132,718) $3.00-$9.00 $5.35 Exercised .................................................. (95,754) $1.81-$6.25 $3.97 --------- Balance at December 31, 2000 ............................... 2,150,641 $0.50-$9.00 $5.00 Granted .................................................... 476,000 $4.56-$15.00 $7.96 Canceled ................................................... (123,634) $3.69-$7.87 $5.71 Exercised .................................................. (60,803) $1.81-$4.62 $3.35 --------- Balance at December 31, 2001 ............................... 2,442,204 $0.50-$15.00 $5.59 Granted .................................................... 1,898,789 $1.80-$8.59 $3.84 Canceled ................................................... (221,869) $1.80-$9.00 $5.97 Exercised .................................................. (156,632) $0.50-$3.87 $2.90 --------- Balance at December 31, 2002 ............................... 3,962,492 $1.80-$15.00 $4.83 =========
At December 31, 2002, options to purchase 2,362,446 shares of common stock were vested and exercisable at exercise prices ranging from $1.80 to $15.00 per share. At December 31, 2001 and 2000, options to purchase 1,576,834 and 1,283,744 shares of common stock were vested and exerciseable, respectively. At December 31, 2002, options to purchase 242,718 shares of common stock were available for future option grants under the Plan. The following table summarizes information about stock options outstanding and exercisable related to the Plan at December 31, 2002:
Options Outstanding Options Exercisable --------------------------------------------------- ----------------------------- Weighted Weighted Weighted Average Average Average Outstanding at Remaining Exercise Exercisable at Exercise Range of Exercise Price December 31, 2002 Contractual Life Price December 31, 2002 Price ----------------------- ----------------- ---------------- ----- ----------------- ----- $1.80 - $3.88 ........ 1,830,078 6.8 years $2.48 1,106,644 $2.90 $4.00 - $6.99 ........ 1,295,114 3.5 years $5.78 789,636 $5.37 $7.00 - $15.00 ....... 837,300 6.7 years $8.52 466,166 $7.91 --------- --------- Total ................ 3,962,492 5.6 years $4.83 2,362,446 $4.72 ========= =========
Director's Stock Option Plan In 1995, Cellegy adopted the 1995 Directors' Stock Option Plan (the "Directors' Plan") to provide for the issuance of non-qualified stock options to eligible outside Directors. When the plan was established, Cellegy reserved 150,000 shares for issuance. From 1996 to 2002, a total of 350,000 shares were reserved for issuance under the Directors' Plan. Options issued under the Plan have a term of 10 years and are generally subject to vesting over 3 years. F-18 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) Activity under the Directors' Plan is summarized as follows:
Shares Price Weighted Under Range Average Option Per Share Exercise Price ------ --------- -------------- Balance at January 1, 2000 .................................. 112,500 $3.25-$8.50 $5.13 Granted ................................................... 70,000 $4.81 $4.81 ------- Balance at December 31, 2000 ................................ 182,500 $3.25-$8.50 $5.01 Granted ................................................... 46,000 $5.50-$6.50 $5.85 ------- Balance at December 31, 2001 ................................ 228,500 $3.25-$8.50 $7.26 Granted ................................................... 64,000 $2.56 $2.56 ------- Balance at December 31, 2002 ................................ 292,500 $2.56-$8.50 $4.61 =======
At December 31, 2002, options to purchase 179,330 shares of common stock were vested and exercisable at exercise prices ranging from $3.25 to $8.50 per share. At December 31, 2002, options to purchase 36,833 shares of common stock were available for future option grants under the Directors' Plan. The following table summarizes information about stock options outstanding and exercisable related to the Directors' Plan at December 31, 2002:
Options Outstanding Options Exercisable --------------------------------------------------- ----------------------------- Weighted Weighted Weighted Average Average Average Outstanding at Remaining Exercise Exercisable at Exercise Range of Exercise Price December 31, 2002 Contractual Life Price December 31, 2002 Price ----------------------- ----------------- ---------------- ----- ----------------- ----- $2.56 - $3.25 .................. 68,000 9.1 years $2.60 4,000 $3.25 $4.50 - $5.50 .................. 206,500 6.2 years $5.08 167,996 $5.09 $6.50 - $8.50 .................. 18,000 7.9 years $6.72 7,334 $7.04 ------- ------- Total .......................... 292,500 6.7 years $4.61 179,330 $5.13 ======= =======
Shares reserved As of December 31, 2002, we have reserved shares of common stock for future issuance as follows: Warrants 300,000 Stock Option Plans 279,551 Neptune Agreement 1,285,000 --------- Total 1,864,551 ========= Warrants to purchase 300,000 shares of our common stock at an average exercise price of $11.75 per share are outstanding as of December 31, 2002. The warrants expire between March and September 2005. Non-cash Compensation Expense related to Stock Options For the year ended December 31, 2002, the Company recorded non-cash compensation expense of $322,000. $72,000 of this expense related to options issued to non-employees under the Equity Incentive Plan and $250,000 related to the extension of the exercise period of certain options issued to employees that were terminated in December 2002 (See Note 13 Restatement). F-19 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) 9. Income Taxes At December 31, 2002 the Company had net operating loss carryforwards of approximately $55,000,000 and $10,000,000 for federal and state purposes, respectively. The federal net operating loss carryforwards expire between the years 2004 and 2022. The state net operating loss carryforwards expire between the years 2004 and 2013. At December 31, 2002, the Company also had research and development credit carryforwards of approximately $1,200,000 and $700,000 for federal and state purposes, respectively. The federal credits expire between the years 2006 and 2022 and the state credits do not expire. Pursuant to the "change in ownership" provisions of the Tax Reform Act of 1986, utilization of the Company's net operating loss and research and development tax credit carryforwards may be limited if a cumulative change of ownership of more than 50% occurs within any three-year period. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax liabilities and assets are as follows (in thousands): December 31, -------------------------- 2002 2001 -------- -------- Deferred tax assets: Net operating loss carryforwards ........ $ 19,300 $ 20,200 Deferred revenue ........................ 6,000 -- Credit carryforwards .................... 1,600 1,900 Capitalized intangibles ................. 1,900 1,800 Other, net .............................. 800 300 -------- -------- Total deferred tax assets .................. 29,600 24,200 Valuation allowance ........................ (29,600) (24,200) -------- -------- Net deferred tax assets .................... $ -- $ -- ======== ======== The valuation allowance for deferred tax assets for 2003, 2002 and 2001 increased by approximately $5,400,000, $5,700,000 and $3,500,000, respectively. 10. Segment Reporting The Company has two business segments: pharmaceuticals and cosmeceuticals. Pharmaceuticals include primarily research and clinical development expenses for potential prescription products to be marketed directly by Cellegy or through corporate partners. Current pharmaceutical revenues consist primarily of Rectogesic sales in Australia, in addition to the PDI License Agreement for Tostrex. The Company expects to complete other corporate collaborations in the future for a number of its potential pharmaceutical products, which may result in milestones, development funding and royalties on sales. Cellegy expects to generate future revenues on potential products it intends to self-market.The cosmeceutical business segment includes development expenses for non-prescription anti-aging products. During 2001 and 2000, Cellegy incurred development expenses for its cosmeceutical products. No development expenses were incurred in 2002. Our product sales are from one customer, Gryphon Development, Inc., which is selling one of the Company's skin care products, exclusively in the United States, through a major specialty retailer. Cellegy allocates its revenues and operating expenses to each business segment, but does not assess segment performance or allocate resources based on a segment's assets and, therefore, asset depreciation and amortization and capital expenditures are not reported by segment. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. F-20 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) The Company's segments are business units that will, in some cases, distribute products to different types of customers through different marketing programs. The potential future sales of cosmeceutical products require a significantly different marketing effort than sales of pharmaceutical products to physicians and other traditional pharmaceutical distribution channels. Pharmaceutical products require more extensive clinical testing and ultimately regulatory approval by the FDA and other worldwide health registration agencies, requiring a more extensive level of development, manufacturing and compliance than a cosmeceutical product. The following table contains information regarding revenues and operating income (loss) of each business segment for the years ended December 31, 2002, 2001, and 2000: Years ended December 31, -------------------------------------------------- 2002 2001 2000 ------------ ------------ ------------ Revenues: (Restated, see note 13) Pharmaceuticals ...... $ 320,339 $ 217,439 $ 196,434 Cosmeceuticals ....... 1,081,287 660,052 1,389,189 ------------ ------------ ------------ $ 1,401,626 $ 877,491 $ 1,585,623 ============ ============ ============ Operating income (loss): Pharmaceuticals ...... $(16,462,264) $(21,021,796) $(13,114,538) Cosmeceuticals ....... 700,837 52,427 1,127,139 ------------ ------------ ------------ $(15,761,427) $(20,969,369) $(11,987,399) ============ ============ ============ Total assets were minimal for the cosmeceutical segment. Revenue from Major Customer Revenues from product sales to one customer represented approximately 70%, 75% and 88% of consolidated revenue for 2002, 2001 and 2000, respectively. Geographic data Approximately 20% of our total revenues are from sales of Rectogesic in Australia. All other sales are in the United States. Primarily all our total assets are located in the United States. 11. Related Party Transactions Cellegy has paid fees to the Company's board members for their services on the board, audit committee and compensation committee. The total fees paid to these directors during 2002, 2001 and 2000 were $10,000, $30,000 and $46,500. There were no consulting fees paid in cash to any board members in 2002. For 2001, consulting fees of $ 80,000 were paid to two board members based on consulting agreements. The Company recognized $33,000 in compensation expense during 2002 for a consulting agreement with a former board member. Cellegy issued stock options to this board member for his consulting services. Cellegy has an interest bearing $100,000 loan outstanding to a non-officer employee, which was issued in conjunction with the purchase of his home. F-21 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) 12. Quarterly Financial Data (unaudited) (amounts in thousands except per share data)
2002 First Second Third Fourth Fourth Quarter Quarter Quarter Quarter Quarter Total -------- -------- -------- -------- -------- -------- (Previously (Restated, (Restated, reported) see note 13) see note 13) -------------------------------------- -------------------------------------- Total revenue ............................ $ 267 $ 150 $ 145 $ 840 $ 840 $ 1,402 Operating loss ........................... (4,642) (5,753) (1,756) (4,306) (3,610) (15,761) Net loss ................................. (4,387) (5,624) (1,623) (4,302) (3,607) (15,241) Basic & diluted net loss per common share .................................. $ (0.25) $ (0.32) $ (0.09) $ (0.24) $ (0.20) $ (0.86)
First Second Third Fourth 2001 Quarter Quarter Quarter Quarter Total -------- -------- -------- -------- -------- Total revenue ...................................... $ 41 $ 53 $ 265 $ 518 $ 877 Operating loss ..................................... (4,206) (4,352) (4,182) (8,229) (20,969) Net loss ........................................... (3,777) (4,156) (3,871) (7,661) (19,465) Basic & diluted net loss per common share .......... $ (0.27) $ (0.29) $ (0.23) $ (0.47) $ (1.26)
13. Restatement In the course of preparing its financial statements for the year ended December 31, 2003, the Company determined that it was necessary to adjust the accounting treatment for certain employee and director stock options that had been cancelled during the fourth quarter of 2002. The Company initially accounted for the cancellation of certain unvested options as a modification to the stock options and applied variable accounting treatment to the uncancelled portion of the stock options. Subsequently, the Company determined that was not the appropriate application under generally accepted accounting principles, and reversed the $695,000 of expense previously recorded in the fourth quarter of 2002 related to the intrinsic value of the vested options. Cellegy will also file amended quarterly reports on Form 10-Q/A for each of the first three quarters of 2003. A summary of the effect of this adjustment on the 2002 financial statements is as follows: in the statement of operations, research and development expense, selling, general and administrative expense and the net loss were reduced by $269,000, $426,000 and $695,000 respectively, on the consolidated balance sheet, common stock and the accumulated deficit were both reduced by $695,000. The following summarized information shows the amounts previously reported and the amounts restated. F-22 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) Consolidated Condensed Balance Sheets
December 31, 2002 -------------------------------------- Previously As reported restated ------------ ------------ Assets Total assets ................................................................... $ 28,379,268 $ 28,379,268 ============ ============ Liabilities and Shareholders' Equity Total liabilities .............................................................. $ 17,844,823 $ 17,844,823 ------------ ------------ Shareholders' equity: Common stock, no par value; 35,000,000 shares authorized: 19,652,356 and 17,295,274 shares issued and outstanding at December 31, 2002 and December 31, 2001, respectively .................... 96,835,062 96,139,764 Accumulated other comprehensive income ......................................... 11,831 11,831 Deficit accumulated during the development stage ............................... (86,312,448) (85,617,150) ------------ ------------ Total shareholders' equity ..................................................... 10,534,445 10,534,445 ------------ ------------ Total liabilities and shareholders' equity ..................................... $ 28,379,268 $ 28,379,268 ============ ============
F-23 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) Consolidated Condensed Statements of Operations
Year Ended Period from June 26, 1989 December 31, (inception) to December 31, 2002 2002 ------------------------------- ------------------------------- Previously As Previously As reported restated reported restated ------------ ------------ ------------ ------------ Revenues: Total revenues ...................... $ 1,401,626 $ 1,401,626 $ 8,347,326 $ 8,347,326 Costs and expenses: Cost of product sold .............. 369,992 369,992 1,320,874 1,320,874 Research and development .......... 10,672,146 10,403,214 61,886,316 61,617,384 Selling, general and administrative 6,816,213 6,389,847 27,376,962 26,950,596 Acquired in-process technology .... -- -- 7,350,102 7,350,102 ------------ ------------ ------------ ------------ Total costs and expenses ............ 17,858,351 17,163,053 97,934,254 97,238,956 ------------ ------------ ------------ ------------ Operating loss ...................... (16,456,725) (15,761,427) (89,586,928) (88,891,630) Other income (expense), net ......... 520,825 520,825 4,722,985 4,722,985 ------------ ------------ ------------ ------------ Net loss ............................ (15,935,900) (15,240,602 (84,863,943) (84,168,645) Non-cash preferred dividends ........ -- -- 1,448,505 1,448,505 ------------ ------------ ------------ ------------ Net loss applicable to common shareholders ........................ $(15,935,900) $(15,240,602) $(86,312,448) $(85,617,150) ============ ============ ============ ============ Basic and diluted net loss per common share .......................... $ (0.90) $ (0.86) ============ ============
F-24 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Condensed Financial Statements - (Continued) Consolidated Condensed Statements of Cash Flows
Year Ended Period from June 26, 1989 December 31, (inception) to December 31, 2002 2002 ------------------------------- ------------------------------- Previously As Previously As reported restated reported restated ------------ ------------ ------------ ------------ Operating activities Net loss ........................................... $(15,935,900) $(15,240,602) $(84,863,943) $(84,168,645) Other operating activities ......................... 17,541,626 16,846,328 31,752,616 31,057,318 ------------ ------------ ------------ ------------ Net cash provided by (used in) operating activities ......................................... 1,605,726 1,605,726 (53,111,327) (53,111,327) Investing activities Net cash provided by (used in) investing activities ......................................... 8,160,931 8,160,931 (7,258,588) (7,258,588) Financing activities Net cash provided by financing activities .......... 6,066,482 6,066,482 81,998,432 81,998,432 ------------ ------------ ------------ ------------ Net increase in cash and cash equivalents .......... 15,833,139 15,833,139 21,628,517 21,628,517 Cash and cash equivalents, beginning of period ..... 5,795,378 5,795,378 -- -- ------------ ------------ ------------ ------------ Cash and cash equivalents, end of period ........... $ 21,628,517 $ 21,628,517 $ 21,628,517 $ 21,628,517 ============ ============ ============ ============
F-25 Cellegy Pharmaceuticals, Inc. (a development stage company) Notes to Consolidated Financial Statements - (Continued) Consolidated Statement of Shareholders' Equity
Previously reported ------------------------------------------------------------------------------------ Accumulated Deficit Other Accumulated Common Stock Comprehensive During the Total ---------------------------- Income Development Shareholders' Shares Amount (Loss) Stage Equity ---------- ------------ ------------ ------------ ------------ Balances at December 31, 2001 ......... 17,295,724 $ 90,137,811 $ 83,458 $(70,376,548) $ 19,844,721 Exercise of options to purchase common stock ................ 156,632 454,983 -- -- 454,983 Issuance of 2,200,000 common stock in connection with the private placement of common stock in November 2002, net of issuance cost of $275,000 .......................... 2,200,000 5,225,000 -- -- 5,225,000 Compensation expense for options related to non-employees ........................ -- 72,224 -- -- 72,224 Compensation expense related to stock option modifications ........................ -- 945,044 -- -- 945,044 Unrealized gain (loss) on investments .......................... -- -- (82,916) -- (82,916) Foreign currency translation .......... -- -- 11,289 -- 11,289 Net loss .............................. -- -- -- (15,935,900) (15,935,900) ------------ ------------ Total Comprehensive Loss .............. -- -- -- -- -- Balances at December 31, 2002 ......... 19,652,356 $ 96,835,062 $ 11,831 $(86,312,448) $ 10,534,445 ============ ============ ============ ============ ============
As restated ------------------------------------------------------------------------------------ Accumulated Deficit Other Accumulated Common Stock Comprehensive During the Total ---------------------------- Income Development Shareholders' Shares Amount (Loss) Stage Equity ---------- ------------ ------------ ------------ ------------ Balances at December 31, 2001 ......... 17,295,724 $ 90,137,811 $ 83,458 $(70,376,548) $ 19,844,721 Exercise of options to purchase common stock ................ 156,632 454,983 -- -- 454,983 Issuance of 2,200,000 common stock in connection with the private placement of common stock in November 2002, net of issuance cost of $275,000 .......................... 2,200,000 5,225,000 -- -- 5,225,000 Compensation expense for options related to non-employees ........................ -- 72,224 -- -- 72,224 Compensation expense related to stock option modifications ........................ -- 249,746 -- -- 249,746 Unrealized gain (loss) on investments .......................... -- -- (82,916) -- (82,916) Foreign currency translation .......... -- -- 11,289 -- 11,289 Net loss .............................. -- -- -- (15,240,602) (15,240,602) ------------ ------------ Total Comprehensive Loss .............. -- -- -- -- (15,312,229) ------------ Balances at December 31, 2002 ......... 19,652,356 $ 96,139,764 $ 11,831 $(85,617,150) $ 10,534,445 ============ ============ ============ ============ ============
F-26 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ---------- EXHIBITS to Form 10-K/A Under THE SECURITIES EXCHANGE ACT OF 1934 ---------- CELLEGY PHARMACEUTICALS, INC.